Medical University of South Carolina

MEDICA
MUSC Theses and Dissertations
2018

Protective Role of Kallistatin in Vascular Injury, Senescence and
Aging
Youming Guo
Medical University of South Carolina

Follow this and additional works at: https://medica-musc.researchcommons.org/theses

Recommended Citation
Guo, Youming, "Protective Role of Kallistatin in Vascular Injury, Senescence and Aging" (2018). MUSC
Theses and Dissertations. 268.
https://medica-musc.researchcommons.org/theses/268

This Dissertation is brought to you for free and open access by MEDICA. It has been accepted for inclusion in
MUSC Theses and Dissertations by an authorized administrator of MEDICA. For more information, please contact
medica@musc.edu.

Protective Role of Kallistatin in Vascular Injury,
Senescence and Aging
by
Youming Guo

A dissertation submitted to the faculty of the Medical University of South Carolina
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in
the College of Graduate Studies.

Department of Biochemistry and Molecular Biology
2018

Approved by:
Chairman, Advisory Committee
Julie Chao
Lee Chao
Robin Muise-Helmericks
Yi-Te Hsu

Hongkuan Fan

ACKNOWLEDGEMENTS

It is with deep respect that I offer my gratitude to my mentor Dr. Julie Chao for
the training, guidance and support. Her continual encouragement has enriched my
graduate training and made it an excellent experience. I would also thank my advisory
committee members, Drs. Lee Chao, Robin Muise-Helmericks, Yi-Te Hsu and Hongkuan
Fan, for their valuable advice, wisdom and assistance on my research project.
Meanwhile, I would like to thank my workmates who have aided me in experimental
design, laboratory techniques and result interpretation, particularly Drs. Pengfei Li and
Zhirong Yang. Finally, I am forever indebted to my family for their understanding, support
and encouragement during my four years’ graduate training.

II

TABLE OF CONTENTS
Page
ACKNOWLEDGEMENTS………………………………………….…………………………...II
LIST OF FIGURES………………………………………………………………………………V
ABSTRACT………………………………………………………………...………………….VIII
ABBREVIATIONS……………………………………………………………………………….X
I.

GENERAL INTRODUCTION……………………………………………..………………..1

II.

TO

DETERMINE

THE

ROLE

AND

MECHANISM

OF

KALLISTATIN

IN

ENDOTHELIAL-MESENCHYMAL TRANSITION
Summary………………………………………………………………………………..14
Introduction……………………………………………………...……………………..15
Materials and Methods………………………………………………………………..17
Results…………………………………………………………………...………….…..20
Discussion………………………………………………………………………….…..31
III. TO DETERMINE THE ROLE AND MECHANISM OF KALLISTATIN IN VASCULAR
SENESCENCE AND AGING
Summary………………………………………………………………………….…....36
Introduction……………………………………………………………….…………...37
Materials and Methods………………………………………….……………….…..39
Results…………………………………………………………………………….…....43
Discussion…………………………………………………………………………......62
IV. TO DETERMINE THE ROLE OF ENDOGENOUS KALLISTATIN IN ENDOTHELIAL
SENESCENCE, VASCULAR AND ORGAN INJURY
Summary………………………………………………………………….………….…69

III

Introduction…………………………………………………………...………………..70
Materials and Methods……………………………………………………….……….73
Results………………………………………………………………………….……….79
Discussion……………………………………………………………………….……..98
V. GENERAL DISCUSSION…………………………………………………………….…..103
VI. APPENDICES………………………………………………………………………….....108
VII. REFERENCES……………………………………………………….…………………..129

IV

LIST OF FIGURES
Page
Figure 1-1.

Molecular model of human kallistatin according to α1-antitrypsin…….3

Figure 2-1 A&B.

Kallistatin inhibits TGF-β-induced EndMT…………….……………….21

Figure 2-1 C&D.

Kallistatin inhibits TGF-β-induced EndMT…..…….…………………..22

Figure 2-1 E.

Kallistatin inhibits TGF-β-induced EndMT marker expression…..…..23

Figure 2-2.

Kallistatin inhibits TGF-β-induced ROS formation and NADPH oxidase
expression and activity in human endothelial cells …………………..25

Figure 2-3.

Kalistatin inhibits TGF-β-induced miR-21-Akt signaling in human
endothelial cells ……………………………………..............................26

Figure 2-4.

Kallistatin via its heparin-binding site inhibits miR-21 synthesis, ROS
formation and Snail 1 expression in human endothelial cells….........28

Figure 2-5.

The active site of kallistatin is essential for increasing the expression of
eNOS, SIRT1 and FoxO1 via a tyrosine kinase ………………...…....29

Figure 2-6.

Signaling pathway by which kallistatin inhibits EndMT..……………...30

Figure 3-1.

Kallistatin inhibits TNF-α-induced EPC senescence….......................44

Figure 3-2 A-C.

Kallistatin inhibits TNF-α-induced oxidative stress in EPCs…………45

Figure 3-2 D&E. Kallistatin inhibits TNF-α-induced miR-21 and p16INK4a synthesis in
EPCs.………………………………………………................................47
Figure 3-3.

Kallistatin stimulates SIRT1, eNOS, and catalase expression and
prevents TNF-α-mediated inhibition of these genes in EPCs….........48

Figure 3-4 A-D.

Kallistatin though inhibiting miR-34a upregulates antioxidant genes
SIRT1, eNOS and catalase in EPCs…….......................................... 49

Figure 3-4 E.

miR-34a mimic abolishes the anti-senescent effect of kallistatin in
EPCs…………………………………………….…………………………51

V

Figure 3-5.

The active site of kallistatin is essential for modulating miR-34a, eNOS,
and SIRT1 synthesis through interacting with a tyrosine kinase in
EPCs……………………………………………………………………….52

Figure 3-6 A-D.

Kallistatin attenuates vascular aging, superoxide production, and miR21 synthesis in aortas of diabetic mice…………………………………54

Figure 3-6 E-J.

Kallistatin inhibits miR-34a synthesis and stimulates antioxidant gene
expression in the aorta of diabetic mice…………………………….....55

Figure 3-7 A.

Kallistatin inhibits paraquat-induced superoxide formation in
C. elegans.…………….……………………………………………….…..56

Figure 3-7 B-D.

Kallistatin enhances C. elegans longevity under oxidative stress……57

Figure 3-7 E-G.

Kallistatin enhances C. elegans survival under heat stress………….59

Figure 3-7 H-K.

Kallistatin inhibits miR-34 but stimulates sir-2.1 and sod-3 expression
in C. elegans………………………………………………………………60

Figure 3-8.

Signaling mechanism by which kallistatin inhibits vascular senescence
and aging………………………………………………….......................61

Figure 4-1.

Kallistatin alleviates H2O2-induced endothelial senescence in human
endothelial cells………………………………………………………….. 80

Figure 4-2 A-D. Kallistatin suppresses H2O2-induced oxidative stress in human
endothelial cells………………………………………….………………..81
Figure 4-2 E-H. Kallistatin suppresses H2O2-induced inflammation and miR-34a
synthesis in human endothelial cells……………………………………82
Figure 4-3 A-D.

Kallistatin stimulates antioxidant gene expression and prevents H2O2mediated inhibition of these genes in human endothelial cells.…......84

Figure 4-3 E-H. Kallistatin inhibits H2O2-induced senescence and oxidative stress
through SIRT1-eNOS pathway in human endothelial cells.……….…85

VI

Figure 4-4 A-E.

Kallistatin stimulates Let-7g to inhibit miR-34a and elevate SIRT1 and
eNOS synthesis in human endothelial cells.…………………………..86

Figure 4-4 F-J.

Kallistatin through Let-7g induction stimulates SIRT1 and eNOS, and
inhibits endothelial senescence, oxidative stress and inflammation..88

Figure 4-5.

Identification of kallistatin deficiency in isolated mouse lung endothelial
cells……………………………………………………….........................89

Figure 4-6 A-E. Kallistatin deficiency in mouse lung endothelial cells increases
senescence and oxidative stress…………………………………….....91
Figure 4-6 F-H.

Kallistatin deficiency in mouse lung endothelial cells exacerbates
inflammatory gene expression………………………………………….92

Figure 4-7.

Kallistatin deficiency inhibits the synthesis of Let-7g and antioxidant
genes and elevates miR-34a in mouse lung endothelial cells………93

Figure 4-8 A-E.

Kallistatin depletion exacerbates aortic oxidative stress in STZ-induced
diabetic mice………………………………………………………………95

Figure 4-8 F-J.

Kallistatin depletion exacerbates renal injury and fibrosis in STZinduced diabetic mice…………………………....………………………96

Figure 4-9.

Signaling pathway by which kallistatin inhibits endothelial senescence,
oxidative stress and inflammation………………………………………97

VII

YOUMING GUO. Protective Role of Kallistatin in Vascular Injury,
Senescence and Aging (Under the direction of JULIE CHAO)

Kallistatin, a plasma protein, consists of two essential structural elements, an
active site and a heparin-binding domain. Kallistatin exerts pleiotropic effects on
angiogenesis, inflammation, fibrosis and tumor growth. This study aims to decipher the
role and mechanism of kallistatin in vascular injury, senescence and aging. First, we
determined the effect of kallistatin on endothelial-mesenchymal transition (EndMT), a
process mediating vascular injury, organ fibrosis and cancer progression. Recombinant
human kallistatin via its heparin-binding site blocked TGF-β-induced EndMT, associated
with downregulated microRNA (miR)-21-Akt signaling and oxidative stress in human
endothelial cells. Kallistatin’s active site is essential for stimulating antioxidant genes,
endothelial nitric oxide synthase (eNOS) and sirtuin 1 (SIRT1) by interacting with a
tyrosine kinase. These findings indicate that kallistatin suppresses EndMT by inhibiting
miR-21-Akt signaling and oxidative stress. Secondly, we determined the role and
mechanism of kallistatin in vascular senescence and aging. Kallistatin antagonized TNFα-induced senescence and oxidative stress, and inhibited miR-34a, a senescence
inducer, leading to elevated SIRT1/eNOS synthesis in human endothelial progenitor
cells. Kallistatin administration in streptozotocin (STZ)-induced diabetic mice attenuated
aortic senescence associated with reduced miR-34a and elevated SIRT1/eNOS levels.
Consistently, kallistatin delayed stress-induced organismal aging in Caenorhabditis
elegans by inhibiting miR-34 and elevating the longevity gene, sir-2.1 (SIRT1 homolog)
synthesis. Therefore, kallistatin reduces vascular senescence and aging by inhibiting
miR-34a-SIRT1/eNOS pathway. Thirdly, we determined the role of endogenous
kallistatin in endothelial senescence, oxidative stress and inflammation by generating
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two strains of kallistatin knockout mice, endothelial cell-specific and general kallistatin
knockout mice. Kallistatin via inducing an endo-protective miRNA Let-7g antagonized
miR-34a-SIRT1-eNOS pathway and inhibited senescence, oxidative stress and
inflammation in human endothelial cells. Conversely, kallistatin deficiency in mouse lung
endothelial

cells

aggravated

H2O2-induced

senescence,

oxidative

stress

and

inflammation associated with downregulated Let-7g and antioxidant genes and
upregulated miR-34a synthesis, indicating that kallistatin protects against endothelial
senescence by modulating Let-7g mediated miR-34a-SIRT1-eNOS pathway. Moreover,
systemic depletion of kallistatin exacerbated aortic oxidative stress and renal fibrosis in
STZ-induced diabetic mice. These studies indicate that kallistatin plays a novel role in
protection against vascular injury, senescence and aging by regulating Let-7g, miR-34a
and miR-21 synthesis, and antioxidant gene expression.
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CHAPTER I

GENERAL INTRODUCTION

Biochemical and Molecular Properties of Kallistatin
Kallistatin was first identified in human plasma as a tissue kallikrein-binding
protein (KBP) in 1986 (Chao et al., 1986). Tissue kallikrein is a serine proteinase which
cleaves low molecular weight kininogen to release vasoactive kinin peptide (Bhoola et
al., 1992). Intact kinin binds to kinin B2 receptors and induces vasodilation and a wide
spectrum of biological effects (Regoli et al., 1990). Purified and
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I-labeled human tissue

kallikrein and human serum rapidly forms a high molecular weight complex, which is
resistant to SDS treatment and boiling, indicating a covalent linkage between tissue
kallikrein and a serum protein (Chao et al., 1986). Molecular cloning and sequence
analyses indicate that KBP is a novel serine proteinase inhibitor (serpin) (Zhou et al.,
1992, Chai et al., 1993).

KBP was designated as kallistatin as it inhibited tissue

kallikrein activity (Zhou et al., 1992, Chai et al., 1993, Chai et al., 1994). Kallistatin is an
acidic glycoprotein with a molecular mass of 58-60 kDa and isoelectric points of 4.6 to
5.2 (Chao et al., 1990, Zhou et al., 1992). The amino acid sequence derived from human
kallistatin cDNA shares 44-46% homology with other human serpins (Chai et al., 1993).
Kallistatin

belongs

to

the

serpin

superfamily

including

α1-antitrypsin,

α1-

antichymotrypsin, protein C inhibitor, plasminogen activator inhibitor, and heparin
cofactor (Rosenberg & Damus, 1973, Baker et al., 1980, Chao et al., 1990, Ehrlich et al.,
1991). Human kallistatin gene is located on chromosome 14q31-32.1 within a serpin
gene cluster (Billingsley et al., 1993, Chai et al., 1994). The kallistatin gene has a typical
five exon-four intron gene structure. The full-length human kallistatin cDNA encodes 427
amino acid residues (Chai et al., 1993, Chai et al., 1994).

The three-dimensional structure of human kallistatin created by molecular
modeling showed that kallistatin consists of three β-sheets and eight α-helices, a
property similar to other serpins (Chen et al., 2000, Chen et al., 2001). Kallistatin
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contains two structural elements: an active site and a heparin-binding domain (Chen et
al., 2000, 2000, Chen et al., 2001). Human kallistatin is a unique serpin as it contains a
reactive center sequence, Phe-Phe-Ser (P2-P1-P1’), for the cleavage site of tissue
kallikrein (Chen et al., 2000).

Moreover, heparin prevents the formation of tissue

kallikrein-kallistatin complex and inhibitory effect of kallistatin on tissue kalllikrein’s
enzymatic activity, leading to the identification of a major heparin-binding site in
kallistatin (Chen et al., 2001). The basic residues, particularly Lys312-Lys313, in the
region between the H helix and C2 sheet of kallistatin, comprise a major heparin-binding
site (Chen et al., 2001). Kallistatin via its two structural domains regulates multiple
signaling pathways and a wide spectrum of biological activities.

Figure 1-1. Molecular model of human kallistatin according to α1-antitrypsin. Active site
is located in the reactive center loop, heparin-binding domain is located between C2
sheet and H helix as indicated by the arrows (Chen et al., 2000; Chen et al., 2001).

Kallistatin via Its Structural Elements Regulates Biological Functions
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Kallistatin through its two functional domains regulates different signaling
pathways independent of tissue kallikrein. On one hand, kallistatin via its active site
inhibits tissue kallikrein’s enzymatic activity, thus the biological function (Chen et al.,
2000). On the other hand, kallistatin via its heparin-binding site interacts with cellular
surface heparan sulfate proteoglycans, thus antagonizing vascular endothelial growth
factor (VEGF)-induced proliferation and migration of human endothelial cells (Miao et al.,
2003). Likewise, kallistatin’s heparin-binding site is essential for competing with tumor
necrosis factor (TNF)-α binding to heparan-sulfate proteoglycans, and thus blocking
TNF-α–induced nuclear factor (NF)-κB activation and inflammatory gene expression in
endothelial cells (Yin et al., 2010). Similarly, kallistatin via the heparin-binding site
antagonized high mobility group box-1 (HMGB1)-mediated inflammation, and EGFmediated caner cell proliferation and invasion (Li et al., 2014, Li P. et al., 2016). Thus,
through the active site and heparin-binding domain, kallistatin exerts pleiotropic
functions, including inhibition of angiogenesis, inflammation and cancer development
(Chen et al., 2000, Miao et al., 2003, Yin et al., 2010, Li et al., 2014, Li et al., 2016).

Distribution and Expression of Kallistatin
Kallistatin is mainly synthesized in the liver, and is widely distributed in organs
relevant to cardiovascular function (Chao & Chao, 1995). Human kallistatin transcripts
and protein can be detected in the plasma, liver, heart, lung, kidney, prostate gland and
aorta (Chai et al., 1993, Chao & Chao, 1995, Chao et al., 1996). Kallistatin is also
localized in endothelial cells and smooth muscle cells of large, medium, and small blood
vessels (Wolf et al., 1999). Circulating kallistatin levels are markedly decreased in
animal models of hypertension, streptozotocin (STZ)-induced diabetes mellitus,
lipopolysaccharide

(LPS)-induced

endotoxemia,
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renal

injury

and

hepatocellular

carcinoma (Chao et al., 1990, Chao et al., 1996, Chen et al., 1997, Shen et al., 2008, Zhi
et al., 2015). Importantly, kallistatin levels are significantly lower in patients with liver
disease, septic syndrome, diabetic retinopathy, severe pneumonia, inflammatory bowel
disease, and colon and prostate cancer (Chao et al., 1996, Ma et al., 1996, Stadnicki et
al., 2003, Lin et al., 2013, Chao et al., 2016). Moreover, reduced plasma kallistatin levels
are associated with adiposity and cardiometabolic risk in apparently healthy African
American youths (Zhu H. et al., 2013). These findings indicate that kallistatin is reduced
under various pathological conditions, implicating the involvement of kallistatin in
cardiovascular damage.

Kallistatin Is A Vasodilator Independent of Tissue Kallikrein
The first pivotal finding regarding kallistatin’s function in vascular biology is
kallistatin-mediated reduction of blood pressure. The levels of kallistatin mRNA and
protein in tissues and serum are significantly lower in spontaneously hypertensive rats
compared with normotensive control rats (Chao & Chao, 1988). Moreover, the
expression of the hepatic kallistatin is markedly reduced in N-nitroarginine methyl ester
(L-NAME)-induced arterial hypertensive rats (Chao et al., 1996). Overexpression of rat
kallistatin in transgenic mice results in significant reduction in blood pressure compared
with the control littermates (Chen et al., 1996). These findings indicate a potential role of
kallistatin in blood pressure regulation. Importantly, kallistatin was identified to be a
potent vasodilator in 1997 (Chao et al., 1997). Human kallistatin administration produced
a rapid and transient reduction in mean arterial blood pressure in rats, and caused
vasorelaxation in aortic rings and perfused rat kidney (Chao et al., 1997). Additionally,
the blood pressure-lowering effect induced by kallistatin is independent of its interaction
with tissue kallikrein, as icatibant (Hoe 140), a bradykinin B2-receptor antagonist, had no
effect on the hypotensive effect of kallistatin but abolished kallikrein/kinin-mediated blood
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pressure reduction (Chao et al., 1997). Moreover, the nitric oxide synthase inhibitor, LNAME blocked kallistatin-mediated vasodilatory effect in rats (Chao et al., 2016),
indicating that kallistatin induces vasodilation, in part, through stimulation of NO
production. Therefore, these findings indicate that kallistatin is a vasodilator and plays a
role in maintaining normal blood pressure unrelated to the interaction with tissue
kallikrein.

Kallistatin Inhibits Vascular Inflammation
TNF-α, a potent pro-inflammatory cytokine, activates the transcription factor NFκB and promotes inflammatory gene expression, leading to increased oxidative stress,
vascular inflammation and endothelial dysfunction (Lawrence, 2009). In cultured
endothelial cells, kallistatin via the heparin-binding site inhibited TNF-α-induced NF-κB
activation and monocyte adhesion to endothelial cells, as well as cell adhesion molecule
and cytokine expression, including ICAM-1, VCAM-1 and MCP-1 (Shen et al., 2009, Yin
et al., 2010). Moreover, kallistatin gene delivery attenuated mouse vascular leakage
induced by complement factor C5a, and reduced VEGF-induced endothelial cell
permeability (Yin et al., 2010). Kallistatin gene or protein therapy alleviated joint swelling
and inflammation in rats with joint arthritis, inhibited renal inflammation in diabetic db/db
mice and caecal ligation and puncture (CLP)-induced septic mice, and ameliorated lung
injury and inflammation in LPS-challenged mice (Yin et al., 2010, Li et al., 2014, Lin et
al., 2015, Yiu et al., 2016). Kallistatin also antagonized the pro-inflammatory mediator
HMGB1-induced inflammatory cytokine expression through its heparin-binding site in
endothelial cells (Li et al., 2014). Moreover, kallistatin via interaction with the
transcription factor kruppel like factor (KLF) 4 induced eNOS expression, leading to the
inhibition of vascular inflammation (Shen et al., 2009). eNOS promotes bioavailable NO
production. NO plays a critical role in inhibiting inflammatory gene expression by
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preventing NF-κB activation (Matthews et al., 1996). Overall, these findings indicate that
kallistatin exhibits potent anti-inflammatory actions.

Kallistatin Inhibits Endothelial Apoptosis
Cell apoptosis, the programmed cell death, occurs in both physiological and
pathological conditions in the cardiovascular system. The pathogenesis of cell apoptosis
is commonly implicated in heart failure, myocardial infarction and other cardiovascular
diseases (Bennett, 2002). The cardiomyocytes in cardiac tissue and endothelial cells in
vascular wall are the typical cells afflicted by apoptosis. Kallistatin has been shown to
attenuate cardiomyocyte apoptosis in rats at 1 day after acute myocardial ischemiareperfusion (I/R) injury, and reduce renal tubular necrosis in mice with I/R (Chao et al.,
2006, Zhou et al., 2015). Kallistatin-mediated anti-apoptotic actions in the kidney and
heart suggest the potential protective role of kallistatin in vascular rarefaction. Indeed,
kallistatin gene delivery prevented glomerular capillary loss in hypertensive rats (Shen et
al., 2010, Gao et al., 2014). However, depletion of endogenous kallistatin augmented
endothelial loss and aortic oxidative injury in deoxycorticosterone acetate (DOCA)-salt
induced hypertensive rats (Liu Y. et al., 2012, Gao et al., 2014). These studies
substantiate the role of kallistatin in vascular protection.

Endothelial cells line the blood vessel and compose the inner layer of blood
vessel wall. Kallistatin has the ability to attenuate TNF-α-induced endothelial apoptosis
through inhibition of reactive oxygen species (ROS) and activation of Akt-eNOS
signaling (Shen et al., 2010). Circulating endothelial progenitor cells (EPCs) are a subset
of mononuclear cells derived from bone marrow that have regenerative capacity to
differentiate into mature endothelial cells (Yoder, 2012). Reduced EPC number is
associated with defective proliferation and mobility as well as accelerated apoptosis and
7

senescence (Imanishi et al., 2008). Kallistatin gene transfer increased circulating EPC
number in hypertensive rat model, and promoted EPC migration, adhesion and tube
formation associated with NO stimulation in vitro (Gao et al., 2014). In contrast,
kallistatin depletion by kallistatin neutralized antibody injection decreased EPC levels
and exacerbated vascular oxidative stress and endothelial rarefaction (Liu Y. et al.,
2012, Gao et al., 2014). Collectively, kallistatin protects against vascular injury via
attenuating endothelial cell apoptosis and enhancing EPC mobility and function.

Kallistatin Protects against Oxidative Organ Damage
Oxidative Stress plays a pivotal role in pathological events such as inflammation
and organ injury. Inhibition of oxidative stress is crucial for alleviation of oxidative multiorgan damage. Time-dependent elevation of circulating ROS levels are associated with
reduced kallistatin levels in animal models of hypertension and renal injury (Shen et al.,
2008, Shen et al., 2010). Kallistatin’s antioxidant activity has been exhibited in multiple
animal models, including hypertension, myocardial infarction, sepsis and diabetes (Chao
et al., 2006, Shen et al., 2008, Shen et al., 2010, Li et al., 2015, Yiu et al., 2016). With its
antioxidant activity, kallistatin administration reduced organ injury and improved survival
in mice with CLP-induced polymicrobial sepsis, and alleviated LPS-induced acute lung
injury in mice (Huang et al., 2014, Li et al., 2014, Lin et al., 2015). Kallistatin gene
transfer displayed a renoprotective effect partially by its antioxidant action in diabetic
db/db mice (Yiu et al., 2016). Moreover, kallistatin gene delivery attenuated organ
damage in conjunction with decreased ROS formation and increased eNOS and NO
levels in animal models of myocardial infarction and hypertension (Chao et al., 2006,
Shen et al., 2008, Shen et al., 2010). Conversely, endogenous kallistatin depletion by
neutralizing

antibody

injection

aggravated

cardiovascular

and

renal

lesions,

accompanied by elevated oxidative stress, inflammation and hypertrophy in hypertensive
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rats (Liu Y. et al., 2012). NO is capable of inhibiting NADPH oxidase activity (Selemidis
et al., 2007), thus promoting NO bioavailability should lead to the attenuation of oxidative
stress. Kallistatin increases NO formation by activating Akt-eNOS signaling pathway
(Shen et al., 2010, Gao et al., 2014). Moreover, kallistatin via NO formation inhibits
NADPH oxidase activity provoked by TNF-α, H2O2 or angiotensin II in cultured renal
cells, cardiomyocytes, myofibroblasts, EPCs and endothelial cells (Gao et al., 2008,
Shen et al., 2008, Shen et al., 2009, Shen et al., 2010, Yin et al., 2010, Gao et al.,
2014). Taken together, these findings indicate that kallistatin through its antioxidant
actions protects against multi-organ damage.

Kallistatin Inhibits Organ Fibrosis and Tumor Growth
Myofibroblast accumulation, aberrant angiogenesis and vascular remodeling are
the common features of organ fibrosis and tumor growth (Wynn, 2008). Kallistatin
administration attenuated salt-Induced renal fibrosis and collagen expression in
hypertensive rats, and reduced carbon tetrachloride-induced liver fibrosis in rats,
associated with decreased oxidative parameter including malondialdehyde level and
superoxide dismutase activity (Huang et al., 2014). Kallistatin overexpression in db/db
diabetic mice allevated glomerulosclerosis and tubular interstitial injury and attenuated
renal fibrosis by inhibiting TGF-β signaling (Yiu et al., 2016). TGF-β is a central regulator
of fibrosis. In contrast, kallistatin depletion by neutralizing antibody injection worsened
renal fibrosis by elevating fibrotic gene expression and myofibroblast number (Liu Y. et
al., 2012). Moreover, adenovirus carrying the human kallistatin gene inhibited tumor
growth in nude mice with human breast tumor xenografts (Miao et al., 2002). Lentivirusmediated kallistatin gene delivery dramatically decreased pulmonary tumor metastasis in
association with reduced angiogenesis and inflammation in mice bearing pulmonary
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tumor (Strait & Lakatta, 2012). Therefore, kallistatin administration displays potential
application value for controlling fibrosis formation and tumor growth and metastasis.

Potential Role of Kallistatin in Vascular Injury, Senescence and Aging
Aging is one of the dominant risk factors for the development of cardiovascular
disease (Lakatta, 2002). It is well known that aging is associated with a decreased
capacity to repair and regenerate damaged blood vessels. Cellular senescence can
acquire

senescence-associated

secretory

phenotype

(SASP)

causes

vascular

rarefaction, inflammation and fibrosis (Clements et al., 2013). Endothelial-mesenchymal
transition (EndMT) remodels vascular structure by rarefaction of endothelial cells but
thickening of smooth muscle layers. EndMT is a critical process mediating organ fibrosis
and tumor progression. Kallistatin has been known to inhibit organ fibrosis and tumor
growth in animal models. It is not yet known whether kallistatin through regulating
EndMT to inhibit organ and vascular injury. Moreover, plasma kallistatin levels are
decreased in multiple aging-associated vascular diseases, including hypertension,
coronary artery disease and diabetes. Plasma kallistatin levels are recently reported to
be positively associated with leukocyte telomere length in African Americans (Zhu et al.
2016). As leukocyte telomere length shortens with age and is a valuable biomarker for
cellular senescence and organismal aging (Shammas, 2011), thus kallistatin may have a
potential protective role in age-related vascular diseases. Oxidative stress is a particular
important inducer of organ fibrosis and vascular senescence (Chen et al., 2008,
Erusalimsky, 2009). Therefore, enhancing cellular antioxidant defense is an effective
means to alleviate vascular injury and aging.

At the molecular level, eNOS plays a crucial role in regulating vascular tone,
proliferation and oxidative stress via NO production (Forstermann & Munzel, 2006).
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SIRT1 as a longevity gene stimulates the expression eNOS and other antioxidant
enzymes, such as manganese superoxide dismutase (MnSOD) and catalase,
contributing to vascular endothelial homeostasis (Chen et al., 2010, Olmos et al., 2013,
Xia et al., 2013). Conversely, microRNA (miR)-34a and miR-21 have emerged as
important regulators of cellular senescence and aging (Ito et al., 2010, Zhu S. et al.,
2013). Let-7g as an endo-protective miRNA, has been shown to improve multiple
endothelial functions by inhibiting senescence and inflammation (Liao et al., 2014). miR21-Akt pathway is also involved in EndMT process (Kumarswamy et al., 2012).
Therefore, kallistatin may exert a novel function in inhibiting vascular injury, senescence
and aging by regulating eNOS, SIRT1, miR-34a, miR-21 and Let-7g. Studying the role
and mechanism of kallistatin in vascular injury, senescence and aging process will foster
the development of kallistatin-based therapeutic strategies for aging-related vascular
diseases.
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Objective
The object of this research project is to determine the role and mechanism of
kallistatin in vascular injury, senescence and aging. To achieve this goal, we generated
two strains of kallistatin knockout mice, systemic kallistatin depletion and endothelial
cell-specific kallistatin depletion. We hypothesized that kallistatin protects against
vascular and organ injury, senescence and aging by downregulating miR-34a and miR21, and upregulating Let-7g and antioxidant genes, SIRT1 and eNOS. We explored the
role of kallistatin in regulating vascular injury and senescence using: 1) recombinant
kallistatin protein administration, and 2) kallistatin deficiency in mouse lung endothelial
cells, and systemic kallistatin deletion in general kallistatin knockout mice.

Specific Aims

I. To determine the role and mechanism of kallistatin in endothelial-mesenchymal
transition.

II. To determine the role and mechanism of kallistatin in vascular senescence and
aging.

III. To determine the role of endogenous kallistatin in endothelial senescence,
vascular and organ injury.
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CHAPTER II

TO DETERMINE THE ROLE AND MECHANISM OF KALLISTATIN IN
ENDOTHELIAL-MESENCHYMAL TRANSITION

13

Summary
Kallistatin exhibits anti-tumor and anti-fibrotic activities in animal models.
Endothelial-mesenchymal transition (EndMT) is one of the underlying mechanisms
contributing to fibrosis and cancer. Endothelial transdifferentiation is also activated and
contributes to the maladaptive remodeling of vasculature, leading to rarefaction of
endothelium and thickening of smooth muscle layers. Transforming growth factor-β
(TGF-β) is the most common inducer of EndMT. Recombinant human kallistatin
treatment blocked TGF-β-induced EndMT in human endothelial cells, as evidenced by
morphological changes as well as increased endothelial marker expression of VEcadherin and CD31, and reduced mesenchymal marker α-SMA expression. Kallistatin
inhibited TGF-β-mediated reactive oxygen species (ROS) formation and NADPH
oxidase expression and activity. Kallistatin blocked TGF-β-induced miR-21-Akt survival
pathway activation, including Akt phosphorylation, NF-κB activation, Snail1 synthesis,
and matrix metalloproteinase 2 synthesis and activation. Kallistatin via its heparinbinding site blocked TGF-β-induced miR-21, Snail1 expression and ROS formation.
Conversely, kallistatin through its active site stimulated the synthesis of endothelial nitric
oxide synthase (eNOS), sirtuin 1 (SIRT1) and forkhead box O1 (FoxO1), via interacting
with a tyrosine kinase. These combined findings reveal that kallistatin suppresses
EndMT by inhibiting TGF-β-induced miR-21-Akt pathway and oxidative stress and
stimulating the expression of antioxidant genes. The study may provide new insights into
the role of kallistatin in vascular and organ injury.
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Introduction
Endothelial–mesenchymal transition (EndMT) is a critical underlying mechanism
for organ fibrosis and tumor metastasis (Lin et al., 2012). In adults, abnormal
differentiation of EndMT-derived fibroblast-like cells results in fibrosis in the heart, kidney
and lung (Zeisberg et al., 2008, Hashimoto et al., 2010, Braitsch et al., 2013). Moreover,
in later stage of vascular disease EndMT is also activated and contribute to the
maladaptive remodeling of vasculature, leading to vascular injury including rarefaction of
endothelium and thickening of smooth muscle layers (Lin et al., 2012, Nicolosi et al.,
2016). TGF-β signaling has been shown to be involved in controlling endothelial and
epithelial plasticity by eliciting their transition to a mesenchymal state (Yoshimatsu &
Watabe, 2011, van Meeteren & ten Dijke, 2012). The TGF-β-Akt-Snail axis is one of the
important pathways in epithelial–mesenchymal transition (EMT) (Peinado et al., 2003).
TGF-β induces Akt activation and nuclear factor-κB (NF-κB) nuclear translocation (Huber
et al., 2004, Meadows et al., 2009), leading to elevated expression of the Snail
transcription factor and thus reduced epithelial (E)-cadherin expression (Julien et al.,
2007). Snail also mediates downregulation of vascular endothelial (VE)-cadherin
expression (Cheng et al., 2013). Typical morphology changes of EndMT include loss of
cell–cell junctions, such as VE-cadherin and CD31, as well as gain of invasive and
migratory properties characterized by mesenchymal markers, including α-smooth muscle
actin (SMA), fibronection and N-cadherin. Additionally, aberrant expression of
microRNAs (miRs) is implicated in EndMT-related diseases. One such miRNA, miR-21
is markedly upregulated during fibrosis and cancer (Kumarswamy et al., 2012, Luo et al.,
2015). It has been reported that TGF-β-induced EndMT is partly regulated by miR-21Akt pathway, as blockade of miR-21 was found to prevent EndMT and inhibit Akt
activation (Kumarswamy et al., 2012). Moreover, reactive oxygen species (ROS)
production further stimulates miR-21 synthesis (Ling et al., 2012), and oxidative stress
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contributes to cell invasion and fibrogenesis. Therefore, miR-21 and ROS are the major
mediators of EndMT, and thus EndMT-associated vascular and organ injury.

Kallistatin gene or protein delivery has been shown to improve cardiac and renal
function, and decrease cardiac and renal fibrosis in conjunction with reduced superoxide
formation and increased eNOS expression and NO production in animal models (Chao
et al., 2006, Gao et al., 2008, Shen et al., 2008). Specifically, kallistatin reduced collagen
accumulation, collagen fraction volume and TGF-β1 expression in the myocardium of
mice with myocardial infarction (Gao et al., 2008). Kallistatin inhibited renal fibrosis and
aortic injury in hypertensive rats (Shen et al., 2008, Shen et al., 2010). Liver fibrosis was
also decreased upon kallistatin treatment via inhibition of oxidative stress (Huang et al.,
2014). Moreover, kallistatin has displayed inhibitory effect on tumor growth in mice with
breast tumor xenografts (Miao et al., 2002). These findings led us to investigate the role
and mechanism of kallistatin in modulating EndMT, the process underlying vascular
injury, fibrosis and cancer.

16

Materials and Methods
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were kindly provided by Dr.
Robin Muise-Helmericks (Medical University of South Carolina). HUVECs were cultured
in endothelial cell basal medium (EBM)-2 supplemented with EGM-2 SingleQuots
(Lonza), and maintained in a humidified atmosphere of 5% CO2 in air at 37°C. HUVECs
were incubated in the presence or absence of kallistatin (1 µM) for 30 min, followed by
the addition of 10 ng/ml TGF-β1 (R&D Systems) for another 24 h (for gene analysis) or
72 h (activity assay or protein expression). Culture media containing TGF-β1 or
kallistatin were replaced every 24 h. In another set of experiments, cells were pretreated
with 5 µM genistein (Sigma) for 30 min, and then further incubated with 2 µM WT-KS,
HM-KS or AM-KS in the presence of 10 µg/ml polymyxin B sulfate (Sigma) for 30 min
followed by stimulation with TGF-β1 for another 24 h.

Purification and Characterization of Recombinant Human Kallistatins
Recombinant human kallistatin was secreted into the serum-free medium of
cultured human embryonic kidney cells (HEK293T). Cultured medium was concentrated
by ammonium sulfate precipitation followed by nickel-affinity chromatography as
described (Chen et al., 2000, Li et al., 2014). Recombinant wild-type kallistatin (WT-KS),
heparin-binding site mutant (K312A/K313A) kallistatin (HM-KS), and active-site mutant
(A377T) kallistatin (AM-KS) were expressed in E. coli and purified as described (Chen et
al., 2000). The purity and identity of human kallistatin were verified by sodium dodecyl
sulfate-poly-acrylamide gel electrophoresis (SDS-PAGE) and western blot using a
specific monoclonal antibody (Chao et al., 1996, Li et al., 2014).

Detection of ROS Formation and NF-κB Activity Assay
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Intracellular ROS generation was detected using the peroxide-sensitive
fluorescent probe 2’, 7’-dichlorofluorescin diacetate (DCFH-DA; Sigma) as described
previously (Shen et al., 2010). Phosphorylated NF-κB activities in nuclear lysates were
determined using ELISA kit (Cell Signaling Technology) according to the manufacturer’s
instructions.

Quantitative Real-time Polymerase Chain Reaction (qRT-PCR)
RNA was isolated from cells using Trizol reagent (Invitrogen) per the
manufacturer’s instructions. Total RNA was reverse-transcribed using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems) for messenger RNA, or microRNA
Reverse Transcription Kit (Applied Biosystems) for microRNA. qRT-PCR was performed
with Taqman Gene Expression Assay (Applied Biosystems). The following human
primers were purchased from Applied Biosystems: 18S (Hs 99999901_sl), U6 (001973),
hsa-miR-21-3p (002438), eNOS (Hs 01574659_ml), MMP2 (Hs 00234422_ml), Snail1
(Hs 00195591_ml), SIRT1 (Hs 01009006_ml), forkhead box O1 (FoxO1) (Hs
01054576_ml), and NADPH oxidase 4 (Nox4) (Hs 00418356_ml). Data were analyzed
with 2−ΔΔCt value calculation using 18S or U6 for normalization.

Measurement of NADPH Oxidase Activity
The enzymatic activity of NADPH oxidase in cell or aortic homogenates was
assessed by lucigenin enhanced chemiluminescence (ECL) as previously described
(Shen et al., 2010). Protein concentrations were measured by Pierce BCA protein assay
kit (Thermo Fisher Scientific). The chemiluminescence signal was corrected for by the
protein concentration of each sample homogenate.

18

Gelatin Zymography
Conditioned HUVEC medium was collected and centrifuged for zymography.
Briefly, the medium was mixed with non-reducing loading buffer and resolved at 125 V
by 10% SDS-PAGE separating gels copolymerized with 1 mg/ml gelatin. The renaturing
buffer (2.5% Triton X-100) was used to restore the enzyme activity. The gels were
incubated in fresh developing buffer at 37°C for 16 h, followed by staining with
Coomassie blue to visualize the proteolytic bands.

Western Blot Analysis
Cells were lysed in lysis buffer supplemented with a protease inhibitor cocktail
(Thermo Fisher Scientific), and separated on a 10% polyacrylamide gel, and transferred
on polyvinylidene difluoride (PVDF) membranes (Amersham Biosciences). After being
blocked for 1 h in a buffer containing 5% nonfat milk, PVDF membranes were then
probed with primary antibodies to phosphorylated Akt (S473), total Akt, CD31, VEcadherin, α-SMA and α-tubulin (Cell Signaling Technology) overnight at 4°C. The
respective horseradish peroxidase-labeled secondary antibodies were then added to the
membrane for 1 h at room temperature. Chemiluminescence was detected by an ECLplus kit (GE Healthcare).

Statistical Analysis
Data are expressed as means ± SE of three independent experiments. Statistical
significance was determined by analysis of variance with Fisher’s probability leastsquares difference test or Student t-test using GRAPHPAD PRISM software. A value of
P < 0.05 was considered statistically significant.
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Results
Kallistatin Inhibits TGF-β-Induced EndMT and Conserves the Endothelial
Phenotype
We first determined the effect of kallistatin on TGF-β1-mediated EndMT in
cultured endothelial cells. Exposure of HUVECs to TGF-β1 for 3 days caused an obvious
alteration in cellular morphology from a polygonal, cobblestone-like shape to a more
spindle, fibroblast-like shape (Figure 2-1 A). In contrast, kallistatin treatment markedly
suppressed the transition by conserving the endothelial phenotype. Cells undergoing
EndMT were characterized with the expression of fibroblast marker α-SMA and
endothelial markers VE-cadherin and CD31. Representative immunostaining showed
that TGF-β1-induced EndMT was associated with reduced CD31 and VE-cadherin levels
(Figure 2-1 B&C) and increased α-SMA levels (Figure 2-1 D). However, upon kallistatin
treatment, most cells were positive for VE-cadherin and CD31, and negative for α-SMA.
These observations were further confirmed by western blot analysis. In the presence of
TGF-β1, VE-cadherin and CD31 protein levels were greatly reduced, and α-SMA protein
levels were increased (Figure 2-1 E). However, kallistatin treatment reversed TGF-β1mediated effects. Quantitative analysis of the western blots verified our results. These
findings demonstrate that kallistatin suppresses EndMT induced by TGF-β.

Kallistatin

Inhibits

TGF-β-Induced

ROS

Formation

and

NADPH

Oxidase

Expression and Activity
We next determined the effect of kallistatin on ROS formation driven by TGF-β1
in endothelial cells. TGF-β1 significantly stimulated ROS formation compared to the
control group, whereas kallistatin reversed TGF-β’s effect by restoring ROS production
to basal levels (Figure 2-2 A). We also evaluated the effect of kallistatin on the NADPH
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A

B

Figure 2-1 A&B. Kallistatin (KS) inhibits TGF-β-induced EndMT. (A) Representative
images of endothelial morphology under light microscope. Original magnification 200✕.
(B) Representative immunofluorescent images of endothelial marker VE-cadherin
expression in human endothelial cells.
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C

D

Figure 2-1 C&D. Kallistatin (KS) inhibits TGF-β-induced EndMT. (C) Representative
immunofluorescent images of endothelial marker CD-31 and (D) mesenchymal marker
α-SMA in human endothelial cells. Original magnification 200 ✕. Nuclei are
counterstained with Hoechst 33342.
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E

Figure 2-1 E. Kallistatin (KS) inhibits TGF-β-induced EndMT marker expression.
Representative western blots of VE-cadherin, CD31 and α-SMA and quantification of
these EndMT makers are shown. n=3. *P <0.05 vs. control.
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oxidase stimulates the production of ROS (Yan et al., 2014). Kallistatin treatment
completely antagonized TGF-β1-induced Nox4 mRNA levels and NADPH oxidase
activity (Figure 2-2 B&C). Therefore, kallistatin can block TGF-β-induced oxidative stress
in endothelial cells.

Kallistatin Prevents TGF-β-Induced miR-21 Synthesis, Akt and NF-κB Activation,
Snail1 Expression, and MMP2 Synthesis and Activation
Since the miR-21-Akt signaling pathway plays an important role in EndMT, we
tested whether kallistatin regulates TGF-β-induced EndMT through this pathway. Our
results showed that TGF-β1 upregulated miR-21 synthesis, but the effect was prevented
by

kallistatin

(Figure

2-3

A).

Kallistatin

also

prevented

TGF-β1-induced

Akt

phosphorylation (Figure 2-3 B). These results indicate that kallistatin blocks TGF-βinduced EndMT by inhibiting the miR-21-Akt pathway. Moreover, kallistatin treatment
attenuated TGF-β1-mediated NF-κB activation (Figure 2-3 C). Since NF-κB leads to the
activation of the Snail transcription factor, we measured Snail1 mRNA levels. TGF-β1
significantly induced Snail1 transcription, whereas kallistatin treatment prevented the
effect (Figure 2-3 D). Furthermore, we analyzed MMP2 synthesis and activation by PCR
and zymography, respectively. TGF-β1 increased MMP2 mRNA levels and activity,
which were abolished by kallistatin (Figure 2-3E). These results indicate that kallistatin
blocks TGF-β-mediated EndMT, in part, by inhibiting the miR-21-Akt-NF-κB pathway,
Snail1 expression, and MMP2 synthesis and activity.

Kallistatin’s Heparin-Binding Site Is Essential for Preventing TGF-β-Induced miR21 Synthesis, Oxidative Stress and Snail1 Expression
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Figure 2-2. Kallistatin (KS) inhibits TGF-β-induced ROS formation and NADPH oxidase
expression and activity in human endothelial cells. (A) Cellular ROS formation
determined by measuring oxidized fluorescent dye DCF counts. (B) QPCR analysis of
mRNA levels of NADPH oxidase 4 (Nox4). (C) NADPH oxidase activity determined by
lucigenin-dependent chemiluminescence. n=3. *P <0.05 vs. other groups.
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Figure 2-3. Kalistatin (KS) inhibits TGF-β-induced miR-21-Akt signaling in human
endothelial cells. (A) QPCR analysis of miR-21. (B) Representative western blot of
phospho-Akt and quantitative analysis. (C) NF-κB activity determined by ELISA. (D)
QPCR analysis of Snail1 mRNA. (E) MMP2 activity was determined by zymography, and
MMP2 mRNA expression was determined by QPCR. n=3. *P < 0.05 vs. other groups.
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We analyzed the role of kallistatin’s heparin-binding site in modulating TGF-β1induced miR-21 synthesis and ROS generation. Wild-type kallistatin significantly
reduced TGF-β1-driven miR-21 expression, whereas heparin-binding site mutant
kallistatin had no effect (Figure 2-4 A). Likewise, wild-type kallistatin, but not heparin
mutant kallistatin, inhibited TGF-β1-induced ROS formation (Figure 2-4 B). Moreover,
kallistatin’s heparin-binding site was found to be essential for abolishing TGF-β1mediated Snail1 expression (Figure 2-4 C). Our results demonstrate that kallistatin
competes with TGF-β1’s ability to bind to heparan sulfate proteoglycans, thus preventing
TGF-β1-mediated signaling. These new findings indicate that kallistatin’s heparin-binding
site plays an important role in antagonizing TGF-β-induced miR-21, ROS formation and
Snail1 expression.

Kallistatin via Its Active Site Stimulates eNOS, SIRT1, and FoxO1 Expression
We next examined the role of kallistatin’s structural elements on the expression
of antioxidant genes in endothelial cells. Our results showed that wild-type kallistatin and
heparin-binding site mutant kallistatin treatment led to a noticeable rise in eNOS, SIRT1
and FoxO1 mRNA levels, whereas active site-mutant kallistatin had no effect (Figure 25). This finding clearly indicates that the active site of kallistatin is crucial for mediating
the expression of eNOS, SIRT1 and FoxO1. Moreover, treatment with genistein, a
tyrosine kinase inhibitor, abolished kallistatin-induced eNOS, SIRT1 and FoxO1
expression (Figure 2-5). These new results show that kallistatin via its active site
interacts with a cell surface tyrosine kinase, thus stimulating expression of the
antioxidant genes eNOS, SIRT1 and FoxO1.
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Figure 2-4. Kallistatin via heparin-binding site inhibits miR-21 synthesis, ROS formation
and Snail 1 expression in human endothelial cells. (A) QPCR analysis of miR-21. (B)
Cellular ROS formation determined by measuring oxidized fluorescent DCF counts. (C)
QPCR analysis of Snail1 mRNA. WT-KS: wild-type kallistatin; HM-KS: heparin-binding
site mutant kallistatin. n=3. *P <0.05 vs. control; #P <0.05 vs. TGF-β.

28

Figure 2-5. The active site of kallistatin is essential for increasing the expression of
eNOS, SIRT1 and FoxO1 via a tyrosine kinase. QPCR analysis of mRNA levels of (A)
eNOS, (B) SIRT1 and (C) FoxO1 in human endothelial cells. GEN, genistein, a tyrosine
kinase inhibitor. WT-KS: wild-type kallistatin; HM-KS: heparin-binding site mutant
kallistatin; AM-KS: active site mutant kallistatin. n=3. * P <0.05 vs. other groups.
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Figure 2-6. Signaling pathway by which kallistatin inhibits EndMT. Kallistatin’s heparinbinding site is responsible for suppression of TGF-β-induced miR-21-Akt signaling and
ROS formation, while its active site is key for stimulating the expression of eNOS, SIRT1
and FoxO1 through interacting with a tyrosine kinase. GEN: genistein, a tyrosine kinase
inhibitor.
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Discussion
This study provides new insights into the protective role of kallistatin in EndMT
and EndMT-associated pathological processes, such as vascular injury and fibrosis. We
showed that kallistatin prevented EndMT by blocking TGF-β1-induced miR-21 synthesis
and oxidative stress, and also by directly stimulating the expression of the antioxidant
genes eNOS, SIRT1 and FoxO1. Moreover, this is the first study to demonstrate that
kallistatin’s structural elements play crucial roles in the differential regulation of TGF-β
signaling and eNOS/SIRT1 expression in human endothelial cells. We found that
kallistatin via its heparin-binding site inhibited TGF-β1-induced miR-21 expression, ROS
formation, and Snail1 synthesis. Conversely, kallistatin’s active site was observed to be
essential for stimulating the expression of eNOS, SIRT1 and FoxO1 (Figure 2-6). Both
eNOS and SIRT1 are responsible for increasing NO production, and NO has been
shown to be an antioxidant by decreasing ROS levels and NADPH oxidase activity
(Clancy et al., 1992). Our previous finding has shown that kallistatin administration
attenuated vascular injury, and cardiac and renal fibrosis in conjunction with reduced
oxidative stress and increased NO production in animal models with hypertension or
myocardial infarction (Gao et al., 2008, Shen et al., 2008). Thus, our findings reveal a
new mechanism that kallistatin, through its structural elements, inhibits vascular injury
and organ fibrosis by antagonizing EndMT process.

miR-21 is an oncogenic microRNA that is overexpressed in most human tumors,
and can thus promote tumor growth and progression by acting on multiple target genes
(Kumarswamy et al., 2011). Increased miR-21 leads to Akt activation, which in turn
upregulates miR-21 in endothelial cells (Thum et al., 2008). These studies are consistent
with

our

findings

that

TGF-β1

stimulated

miR-21

synthesis

and

Akt

phosphorylation/activation; however, kallistatin efficiently blocked TGF-β1-mediated
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effects. Oxidative stress also stimulates miR-21 expresson (Jiang et al., 2014). The
present study showed that kallistatin not only antagonized TGF-β1-mediated miR-21-Akt
activation, but also blocked TGF-β1-induced oxidative stress. Therefore, kallistatin can
attenuate TGF-β-induced EndMT by targeting the miR-21-Akt pathway and oxidative
stress.

The role of TGF-β-induced Akt-NF-κB activation in the context of EndMT is not
well understood. In the EMT process, Akt stimulates the nuclear translocation of the NFκB complex. NF-κB acts as a transcriptional factor for Snail1 and MMP2 expression
(Julien et al., 2007, Yan & Boyd, 2007). During EndMT the basal lamina is degraded by
matrix metalloproteinases, such as MMP2 (Potenta et al., 2008). Snail factors are known
to repress both VE-cadherin and E-cadherin transcription. Consequently, elevated Snail
expression can stimulate the loss of endothelial cell–cell junctions. In the present study,
our results showed that NF-κB was induced by TGF-β1 in endothelial cells undergoing
EndMT, resulting in elevated Snail1 and MMP2 expression and loss of the endothelial
marker VE-cadherin. In contrast, kallistatin treatment blocked TGF-β1-mediated miR-21Akt activation, leading to suppression of TGF-β-induced NF-κB-Snail1/MMP2 signaling.
Thus, these results indicate that kallistatin inhibits EndMT through blockade of TGF-βinduced Akt-NF-κB signaling pathway.

Heparan sulfate proteoglycans are present on the surface of vascular smooth
muscle cells and endothelial cells (Adhikari et al., 2010, Sarrazin et al., 2011). TGF-β1 is
a heparin-binding growth factor, and the ability of TGF-β1 to bind to heparan or related
proteoglycans is the first step to initiate metabolic signals (Chen Q. et al., 2007). Our
previous studies showed that the heparin-binding site of kallistatin is essential for
antagonizing signaling pathways mediated by other heparin-binding proteins, such as
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VEGF, TNF-α, and HMGB1 (Miao et al., 2003, Yin et al., 2010, Li et al., 2014). It is likely
that kallistatin competes with TGF-β1 from binding to heparan sulfate proteoglycans on
the endothelial cells. Indeed, we showed that kallistatin’s heparin-binding site is essential
for preventing TGF-β1-induced miR-21-Akt signaling and ROS formation in endothelial
cells. Therefore, these results provide new information regarding the role of kallistatin’s
heparin-binding site in antagonizing TGF-β-induced signaling.

eNOS-derived NO is an antioxidant by inhibiting NADPH oxidase activity (Clancy
et al., 1992, Fujii et al., 1997). In addition to eNOS/NO, both SIRT1 and FoxO1 are
capable of suppressing ROS formation. SIRT1 can function to deacetylate and activate
eNOS and FoxO1. FoxO1 is known to promote activation of the antioxidant enzyme
manganese superoxide dismutase to scavenge ROS (Storz, 2011). Our present finding
indicates that kallistatin’s active site is responsible for stimulating the expression of the
antioxidant genes eNOS, SIRT1 and FoxO1, and the effect was blocked by genistein, a
tyrosine kinase inhibitor. Thus kallistatin’s active site could interact with a tyrosine kinase
to increase eNOS/SIRT1 expression. The identity of the putative kallistatin-binding
protein or kallistatin receptor on the endothelial cell surface awaits further investigation.

Taken together, the present study indicates that kallistatin has a novel role in
inhibiting EndMT, and new functions of kallistatin’s functional domains have been
identified. Mechanistically, kallistatin through its two structural elements differentially
regulates miR-21, oxidative stress and eNOS expression. Kallistatin’s heparin-binding
site plays an important role in suppressing miR-21-Akt signaling and ROS formation,
whereas its active site is key for stimulating the expression of eNOS, SIRT1 and FoxO1.
Moreover, kallistatin via its active site interacts with a tyrosine kinase to stimulate eNOS
synthesis, which can lead to NO formation and reduced oxidative stress. Thus, kallistatin
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exerts potent antioxidant activity by dual mechanisms: (1) blocking TGF-β-induced
oxidative stress, and (2) increasing eNOS/SIRT1/FoxO1 levels. These new findings
shed light on the pleiotropic functions and mechanisms of kallistatin in the potential
treatment of fibrosis-related vascular diseases.
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CHAPTER III

TO DETERMINE THE ROLE AND MECHANISM OF KALLISTATIN IN
VASCULAR SENESCENCE AND AGING
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Summary
Kallistatin protects against vascular injury by inhibiting oxidative stress in
hypertensive rats and enhancing the mobility and function of endothelial progenitor cells
(EPCs). We further determined the role and mechanism of kallistatin in vascular
senescence and aging using cultured EPCs, streptozotocin (STZ)-induced diabetic mice,
and Caenorhabditis elegans (C. elegans). Human kallistatin significantly decreased
TNF-α-induced EPC senescence, as indicated by reduced senescence-associated βgalactosidase activity, plasminogen activator inhibitor-1 expression, and elevated
telomerase activity. Kallistatin blocked TNF-α-induced superoxide levels, NADPH
oxidase activity, miR-21 expression and cell cycle inhibitor p16INK4a synthesis. The
microRNA (miR)-34a-SIRT1 axis is an important signaling in regulating senescence.
Kallistatin prevented TNF-α mediated inhibition of SIRT1, eNOS, and catalase, and
directly stimulated the expression of these antioxidant enzymes. Importantly, kallistatin
inhibited miR-34a synthesis, whereas miR-34a overexpression abolished kallistatininduced SIRT1/eNOS expression and anti-senescence activity. Kallistatin via its active
site inhibited miR-34a, and stimulated SIRT1 and eNOS synthesis in EPCs, which was
abolished by genistein, indicating an event mediated by tyrosine kinase. Moreover,
kallistatin administration attenuated aortic senescence, oxidative stress, associated with
reduced miR-34a and miR-21 synthesis and increased SIRT1, eNOS, and catalase
levels in STZ-induced diabetic mice. Furthermore, kallistatin treatment reduced
superoxide formation and improved wild-type C. elegans survival under oxidative or heat
stress, although kallistatin’s protective effect was abolished in miR-34 or sir-2.1 (SIRT1
homolog) mutant C. elegans. Kallistatin inhibited miR-34, but stimulated sir-2.1 and sod3 synthesis in C. elegans. These in vitro and in vivo studies provided significant insights
into the role and mechanism of kallistatin in vascular senescence and aging by
regulating miR-34a-SIRT1 pathway.
36

Introduction
EPCs are a major contributor to vascular repair, and can be derived from bone
marrow, circulating mononuclear cells, and cord blood (Lin et al., 2000, Reyes et al.,
2002). Circulating EPCs are the most important cell population for the replenishment of
damaged or senescent endothelial cells. Advanced aging is a major risk factor for
suppressed EPC function (Williamson et al., 2012). Senescent or impaired EPCs
contribute

to

endothelial

dysfunction,

which

is

a

predictor

of

cardiovascular

diseases(Heiss et al., 2005). Type I diabetes is one of cardiovascular-associated
diseases characterized by reduced EPC numbers and vascular repair (Loomans et al.,
2004). Moreover, the nematode C. elegans has a number of distinct advantages that are
useful for understanding the molecular basis of organismal dysfunction underlying agerelated diseases. Due to its short life cycle (3.5 days) and conserved longevity genes
from worm to human (Zhou et al., 2011). C. elegans is an ideal model for investigating
the aging process. Consequently, EPCs, STZ-induced diabetic mice, and C. elegans are
valuable models for examining the mechanisms of vascular senescence and aging.

Oxidative stress is a key inducer of endothelial senescence, with the
inflammatory cytokine TNF-α being the main contributor to reactive oxygen species
(ROS) production (Chen et al., 2008). Upregulation of antioxidant proteins, such as
endothelial nitric oxide synthase (eNOS), sirtuin 1 (SIRT1), catalase, and manganese
superoxide dismutase (MnSOD), has been shown to protect against oxidative stressmediated insults (Wassmann et al., 2004, Ota et al., 2010). eNOS maintains the redox
state of endothelial cells and promotes vasorelaxation through NO production
(Forstermann & Sessa, 2012). SIRT1 is a conservative longevity gene from yeast to
human, and accounts for vascular homeostasis by activating many antioxidant enzymes,
such as eNOS, catalase, and MnSOD, to diminish ROS (Kitada et al., 2016).
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Conversely, growing evidence has shown that miR-34a is a senescence promoter, as it
inhibits SIRT1 through a miR-34a-binding site within the 3’ UTR of SIRT1 (Zhao et al.,
2010). Furthermore, miR-21, a tumor inducer, is also involved in EPC senescence (Zhu
S. et al., 2013). The antioxidant enzymes and pro-senescence miRNAs underlie the
molecular basis for endothelial senescence and aging-associated diseases. Therefore,
exploration of effective molecules or compounds that stimulate longevity gene
expression and inhibit the effects of negative regulators may lead to a prospective
enhancement of vascular integrity and lifespan.

Kallistatin treatment increases circulating EPC number and reduces aortic
oxidative stress in hypertensive rats, whereas kallistatin deficiency decreases EPC
levels and exacerbates oxidative vascular injury (Liu Y. et al., 2012, Gao et al., 2014). In
addition, kallistatin promotes vascular repair by enhancing the viability, migration, and
function of EPCs (Gao et al., 2014). Kallistatin, via NO stimulation, reduces TNF-α
induced superoxide production and NADPH oxidase activity in endothelial cells (Shen et
al., 2010). Moreover, in Chapter II we showed that kallistatin prevented endothelial–
mesenchymal transition (EndMT) by inhibiting TGF-β-induced miR-21 and increasing
SIRT1 synthesis (Guo et al., 2015). However, whether kallistatin through regulating miR34a-SIRT1 pathway affects endothelial senescence has not been explored, in this study
we investigated the potential role of kallistatin in vascular senescence and aging, using
both in vitro and in vivo models.
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Materials and Methods
Isolation and Culture of EPCs
EPCs were isolated from human umbilical cord blood as described (Gao et al.,
2014). The study was approved by the Medical University of South Carolina Human
Research (Pro00017277). EPCs were isolated by density gradient centrifugation using
Ficoll-Paque PLUS (GE Healthcare,) and cultured in endothelial basal medium with 10%
fetal bovine serum and supplements (Lonza).

Senescence-associated β-Galactosidase Staining
EPCs at 80% confluency in 12-well plates were pre-incubated with kallistatin (1
µM) for 30 min and then treated with TNF-α (10 ng/mL) for 6 days. The senescence
phenotype was detected using the β-galactosidase staining kit (Cell Signaling). The
number of positive senescence-associated β-galactosidase (SA-β-gal) cells was
observed by light microscopy (Olympus CK40) in 10 randomly chosen low-power fields
(✕ 200) and expressed as a percentage of counted cells.

Telomerase Activity Assay
EPCs were pre-incubated with or without kallistatin (1 µM) for 30 min prior to the
addition of TNF-α (10 ng/mL) for 24 h. Cells were lysed with non-denaturing lysis buffer.
Telomerase activity was measured using TRAPEZE RT telomerase detection kit (EMD
Millipore).

NADPH Oxidase Activity Assay
The enzymatic activity of NADPH oxidase was assessed as described in Chapter
II. Fluorescence intensity was continuously monitored for 15 min with a TD20/20
luminometer.
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Detection of Superoxide Formation
Cellular ROS generation was detected using the peroxide-sensitive fluorescent
probe 2’, 7’-dichlorodihydrofluorescein diacetate (DCFH-DA; 10 µM, Sigma). To
determine the role of PI3K-Akt-eNOS pathway, EPCs were pretreated with PI3K inhibitor
LY294002 (5 µM) or iNOS inhibitor L-NAME (100 µM) for 30 min in prior to kallistatin
treatment. To quantify ROS levels, EPCs were seeded onto a 96-well fluorescence plate
and treated as above. Relative fluorescence was measured using the fluorescence plate
reader at 485-nm excitation and 535-nm emission. Superoxide levels in aortas were
determined by red fluorescent probe dihydroethidium (DHE; 3 µM Sigma) incubation at
37°C for 30 min at dark. For ROS staining in C. elegans, worms were washed, incubated
with 3 µM DHE for 30 min and anesthetized with 5 mM levamisole (Sigma). C. elegans
were then transferred to glass slides, sealed with 70% glycerol, and imaged with a
fluorescence microscope (Olympus CK40). Fluorescence intensity was analyzed using
IMAGE J software (National Institutes of Health).

RNA Extraction and qRT-PCR
Total RNA was extracted and reversely transcribed as in Chapter II. RT primers
for miRNAs were used as follows: U6 for EPCs and mice, has-miR-34a and has-miR-21
for EPCs, mmu-miR-34a-3p and mmu-miR-21 for mice, and U18 and cel-miR-34 for C.
elegans. Human 18S was internal control gene for quantifying mRNA expression. Mouse
or C. elegans GAPDH was used as internal control gene for quantifying mRNA
expression. The following primers were used: 18S (Hs99999901_s1), U6 snRNA
(001973), p16INK4a (Hs00923894_m1), has-miR-34a (002316), eNOS (Hs01574659_m1),
SIRT1 (Hs01009006_m1), catalase (Hs00156308_m1), PAI-1 (Hs01126606_m1),
GAPDH (Mm99999915_g1), eNOS (Mm00435217_m1), SIRT1 (Mm00490758_m1),
catalase

(Mm00437992_m1),

U18

(001764),
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miR-34

(Ce241995_mat),

GAPDH

(Ce02425762_m1), sir-2.1 (Ce02459018_g1), and sod-3 (Ce02404515_g1). Data were
analyzed with 2-ΔCt value calculation using control genes for normalization.

Western Blot
Proteins from cell lysates or tissue lysates were separated by SDS-PAGE and
immunoblotted as previously described in Chapter II. Primary antibodies were antiSIRT1, anti-eNOS, anti-β-actin, and anti-GAPDH. Chemiluminescence was detected by
the ECL-plus kit (GE Healthcare).

miRNA Transfection
For miR-34a overexpression, EPCs were transfected with 5 pM of miR- 34a
mimic or control miRNA (Fisher Scientific) with Lipofectamine RNAiMAX reagent (Fisher
Scientific) for 12 h according to the manufacturer’s protocol.

Diabetic Mouse Experiments
All procedures complied with the standards for care and use of animal subjects
as stated in the Guide for the Care and Use of Laboratory Animals. The protocol for all
animal studies was approved by the Institutional Animal Care and Use Committee at the
Medical University of South Carolina. Male wild-type C57/BL6 mice (7–8 weeks of age)
were purchased from Harlan. Mice (male, 12-week-old) were fasted for 16 h and
subjected to 6-day continuous intraperitoneal injections of streptozotocin (STZ, 60
mg/kg; Sigma) to induce type 1 diabetes. Sodium citrate buffer alone (0.1 M, pH 4.5)
was injected in control animals. Mice with blood glucose > 250 mg/dL were considered
diabetic and used in this study. A total of 18 mice were randomly assigned to three
groups: control group (n = 6), diabetes group (n = 6), and diabetes + kallistatin group (20
mg/kg body weight, n = 6). Mice were injected with kallistatin intraperitoneally every 2
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days after verification of diabetes. One week after kallistatin injection, the thoracic aorta
was collected for histological analysis or gene expression analysis.

C.elegans Treatments
Wild-type (N2) C. elegans, sir-2.1 mutant strain VC199 (ok434), miR-34 mutant
strain (gk437), and SOD-3::GFP strain CF1553 (muIs84) were obtained from the
Caenorhabditis Genetics Center. C. elegans were cultured and maintained at 25°C on
nematode growth medium (NGM) seeded with E. coli OP50. N2 worms were treated with
different concentrations of kallistatin (1 or 5 µM) from L4 stage (adult) for 3 days. Total
RNA was extracted for QPCR.

Stress Resistance Assay
For heat-shock assay, age-synchronized N2 L4 worms (n = 30) were preincubated with kallistatin (1 or 5 µM), and were cultured with daily exchanged fresh
medium plates. Two days later, adult worms were exposed at 35°C for 6 h. The survival
of worms was recorded after thermal stress by touching or tapping as monitored under
microscope (AmScope). For oxidative stress resistance assay, age-synchronized N2 L4
worms (n = 50) were pre-incubated with or without kallistatin (1 or 5 µM). Next, the three
groups were separately transferred to NGM plates containing 2 mM paraquat (Sigma).
Survival of the worms was scored daily until the death of last worm.

Statistical Analysis
Data are expressed as means ± SE of three independent experiments. Student ttest and analysis of variants were used to assess differences. Survival curves between
treatment groups were compared using the nonparametric log-rank test. A value of P <
0.05 was considered statistically significant.
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Results
Kallistatin Inhibits TNF-α-Induced Cellular Senescence in EPCs
To identify the effect of kallistatin on cellular senescence in cultured EPCs, we
evaluated three senescent markers, including SA-β-gal activity, plasminogen activator
inhibitor-1 (PAI-1) synthesis, and telomerase activity. Six days’ treatment of TNF-α
caused marked increased SA-β-gal positive cell numbers compared with the control
group, whereas pre-incubation with purified human kallistatin significantly reduced TNFα-induced SA-β-gal-positive cells. Kallistatin alone had no effect on EPC senescence
(Figure 3-1 A). Quantitative analysis of SA-β-gal staining confirmed these results (Figure
3-1 B). TNF-α increased PAI-1 synthesis, whereas kallistatin significantly suppressed
PAI-1 expression with or without TNF-α treatment (Figure 3-1 C). Moreover, kallistatin
prevented TNF-α-mediated suppression of telomerase activity in EPCs (Figure 3-1 D).
These results indicate that kallistatin is capable of blocking TNF-α-induced EPC
senescence.

Kallistatin Inhibits TNF-α-Induced Oxidative Stress, and miR-21 and p16INK4a
Synthesis
To further determine kallistatin’s effect on senescence-associated oxidative
stress in EPCs, fluorescence probe DCFH-DA was used to detect cellular ROS
formation. Representative images show that kallistatin inhibited TNF-α-induced
accumulation of cellular ROS in EPCs, and kallistatin’s effect was abolished by
pretreatment with the PI3K inhibitor LY294002 or the NOS inhibitor L-NAME (Figure 3-2
A). Quantitative analysis verified kallistatin’s inhibitory effect on ROS formation (Figure
3-2 B). Likewise, kallistatin suppressed TNF-α-induced NADPH oxidase activity, which
was again abolished by LY294002 or L-NAME (Figure 3-2 C). Kallistatin alone had no
effect on oxidative stress (Figure 3-2 A–C). These results indicate that kallistatin inhibits
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Figure 3-1. Kallistatin (KS) inhibits TNF-α-induced EPC senescence. (A) Representative
images of senescence-associated β-gal staining in EPCs. (B) Quantification of positive
gal staining cells. (C) QPCR analysis of PAI-1. (D) QPCR detection of telomerase
activity. n = 3. *P < 0.05 vs. control, #P < 0.05 vs. TNF-α group.
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C

Figure 3-2 A-C. Kallistatin (KS) inhibits TNF-α-induced oxidative stress in EPCs. (A)
Representative images of ROS formation using fluorescent probe DCFH-DA. (B)
Quantification analysis of ROS production. (C) NADPH oxidase activity determined by
lucigenin chemiluminescence assay. n = 3. *P < 0.05 vs. control, #P < 0.05 vs. TNF-α
group.
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TNF-α-induced oxidative stress via activation of the PI3K-Akt-eNOS signaling pathway.
Kallistatin also antagonized TNF-α-induced miR-21 synthesis (Figure 3-2 D). Moreover,
kallistatin markedly reduced the expression of p16INK4a, a cyclin-dependent kinase
inhibitor known to be a senescence-associated inducer of cell cycle arrest (Figure 3-2
E). Collectively, these results indicate that kallistatin inhibits TNF-α-induced oxidative
stress, and miR-21 and p16INK4a synthesis.

Kallistatin Prevents TNF-α-Mediated Inhibition of SIRT1, eNOS, and Catalase and
Stimulates Antioxidant Gene Expression
We next determined the effect of kallistatin on the antioxidant genes of SIRT1,
eNOS, and catalase. Kallistatin treatment increased SIRT1 protein levels, as determined
by western blot (Figure 3-3 A, top panel). Moreover, kallistatin reversed TNF-α-mediated
inhibition of SIRT1, eNOS, and catalase expression (Figure 3-3 A–C). Additionally,
kallistatin alone stimulated the synthesis of these antioxidant enzymes (Figure 3-3 A–C).
Therefore, kallistatin not only prevented TNF-α-mediated inhibition of eNOS, SIRT1, and
catalase, but also increased the expression levels of antioxidant enzymes.

Kallistatin Stimulates Antioxidant Gene Expression through miR-34a Inhibition
As miR-34a is a key senescence mediator, we examined kallistatin’s effect on
miR-34a. Our results showed that kallistatin markedly inhibited miR-34a synthesis in
EPCs (Figure 3-4 A). To further determine the role of miR-34a in kallistatin-mediated
stimulation of antioxidant genes, miR-34a was overexpressed by transfection of miR-34a
mimic to EPCs. miR-34a overexpression suppressed SIRT1, eNOS, and catalase
expression compared to the mimic control group, and also abolished kallistatin’s
stimulatory effect on these antioxidant genes (Figure 3-4 B–D). Moreover, miR-34a
overexpression abolished kallistatin’s anti-senescence effect, evidenced by SA-β-gal
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E

Figure 3-2 D&E. Kallistatin (KS) inhibits TNF-α-induced miR-21 and p16INK4a synthesis
in EPCs. QPCR analysis of (D) miR-21 and (E) p16INK4a gene expression. n = 3. *P <
0.05 vs. control, #P < 0.05 vs. TNF-α group.
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Figure 3-3. Kallistatin (KS) stimulates SIRT1, eNOS, and catalase expression and
prevents TNF-α-mediated inhibition of these genes in EPCs. (A) Representative western
blot of SIRT1 and QPCR analysis of SIRT1 mRNA levels. (B) QPCR of eNOS mRNA
levels. (C) QPCR analysis of catalase mRNA levels. n = 3. *P < 0.05 vs. control, # P <
0.05 vs. TNF-α group.
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Figure 3-4 A-D. Kallistatin (KS) though inhibiting miR-34a upregulates antioxidant genes
SIRT1, eNOS and catalase in EPCs. QPCR analysis of (A) miR-34a in kallistatin treated
EPCs. QPCR analysis of (B) SIRT1, (C) eNOS and (D) catalase mRNA levels in mimic
control group or miR-34a mimic group. n = 6. *P < 0.05 vs. control or mimic control.
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staining (Figure 3-4 E). These results indicate that kallistatin, by inhibiting miR-34a
synthesis, prevents miR-34a-mediated inhibition of SIRT1 and eNOS expression to
alleviate EPC senescence.

Kallistatin’s Active site Is Essential for Stimulating Antioxidant Gene Expression:
Role of Tyrosine Kinase
To determine which functional domain of kallistatin is essential for the regulation
of miR-34a-SIRT1 pathway, three types of kallistatin, including wild-type kallistatin,
heparin-binding site mutant kallistatin, and active site mutant kallistatin, were used. We
found that both wild-type kallistatin and heparin-binding site mutant kallistatin effectively
inhibited miR-34a synthesis and elevated SIRT1 and eNOS mRNA levels in EPCs, but
active site mutant kallistatin had no such effects (Figure 3-5 A–C). The results indicate
that kallistatin’s active site is essential for modulating the expression of miR-34a, SIRT1,
and eNOS in EPCs. Moreover, genistein, a tyrosine kinase inhibitor, blocked wild-type
kallistatin’s effect in modulating miR-34a, SIRT1, and eNOS synthesis (Figure 3-5 A–C),
implicating the involvement of a tyrosine kinase. Thus, kallistatin’s active site is critical
for downregulation of miR-34a and upregulation of SIRT1 and eNOS.

Kallistatin Attenuates Aortic Senescence, Superoxide Formation Associated with
Decreased miR-34a and miR-21 Synthesis and Increased SIRT1, eNOS, and
Catalase Levels in Diabetic Mice
We further determined kallistatin’s in vivo effect on vascular senescence and
oxidative stress in aortas of STZ-induced diabetic mice. Aortic senescence, identified by
SA-β-gal staining, was increased in diabetic mice compared to control mice, while
kallistatin treatment prevented STZ-induced effect (Figure 3-6 A). Moreover, higher
levels of superoxide formation and NADPH oxidase activity were observed in the aortas
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control

miR-34a
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miR-34a
mimic + KS

Figure 3-4 E. miR-34a mimic abolishes the anti-senescent effect of kallistatin (KS) in
EPCs. (E) Representative images of positive SA-β-gal staining in mimic control and miR34a-overexpressing EPCs, and quantification analysis is shown. n = 6. *P < 0.05 vs.
mimic control.
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Figure 3-5. The active site of kallistatin is essential for modulating miR-34a, eNOS, and
SIRT1 synthesis through interacting with a tyrosine kinase in EPCs. QPCR analysis of
(A) miR-34a, (B) SIRT1 and (C) eNOS. GEN: genistein, a tyrosine kinase inhibitor.
WTKS: wild-type kallistatin; HMKS: heparin-binding site mutant kallistatin; AMKS: active
site mutant kallistatin. n = 3. *P < 0.05 vs. control.
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of STZ-induced diabetic mice, but this observation was reversed by kallistatin
administration (Figure 3-6 B&C). Furthermore, STZ induced a significant increase of
miR-34a and miR-21 synthesis, as well as reduced SIRT1, eNOS, and catalase mRNA
levels in aortas of diabetic mice compared to control mice, while kallistatin administration
reversed STZ-mediated effect (Figure 3-6 D–H). Consistently, aortic SIRT1 and eNOS
protein levels were markedly reduced in diabetic mice compared to control mice, but
were restored by kallistatin administration, as determined by western blot (Figure 3-6
I&J). Consistent with the results derived from cultured EPCs, kallistatin treatment
protects against vascular aging and oxidative stress in diabetic mice by decreasing miR34a and miR-21 synthesis and increasing SIRT1, eNOS, and catalase levels.

Kallistatin Enhances Wild-type C. elegans Lifespan under Oxidative or Heat Stress
Independent of the Presence of miR-34 and sir-2.1
As stress conditions impair C. elegans longevity and induce premature
senescence, we investigated the effect of kallistatin on C. elegans survival under
oxidative or thermal stress. Paraquat was used to induce oxidative damage in three
strains of C. elegans, including wild-type (N2), miR-34 mutant, and sir-2.1 (SIRT1
analogue) mutant worms. Representative images showed that kallistatin (1 or 5 µM)
markedly reduced paraquatinduced superoxide formation in C. elegans, as identified by
red fluorescence probe DHE, and the result was confirmed by quantitative analysis
(Figure 3-7 A). Moreover, the mean lifespan of wild-type C. elegans was 13.3 ± 0.9 days
under normal condition at 25°C, but was shortened to 7.7 ± 0.3 days under paraquatinduced oxidative stress. Pretreatment with 1 or 5 µM kallistatin reduced the sensitivity to
paraquat and increased mean lifespan of C. elegans by 5.8% or 20.5% (8.2 ± 0.3 or 9.3
± 0.4 days), respectively (Figure 3-7 B). However, kallistatin treatment had no effect on
the lifespan of miR-34 or sir-2.1 mutant worms under oxidative stress (Figure 3-7 C&D).
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Figure 3-6 A-D. Kallistatin (KS) attenuates vascular aging, superoxide production, and
miR‐21 synthesis in aortas of diabetic mice. (A) Representative images of SA‐β‐gal
staining in thoracic aortas from control mice, STZ‐induced diabetic mice, and KS‐treated
diabetic mice. (B) Representative images of superoxide formation labeled by red
fluorescence dye hydroethidine (DHE). (C) NADPH oxidase activity measured by
lucigenin chemiluminescence assay in mouse aortas. (D) QPCR analysis of miR-21 in
mouse aorta. STZ: streptozotocin. n=6. *P < 0.05 vs. control group; #P < 0.05 vs. STZ
group.
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Figure 3-6 E-J. Kallistatin (KS) inhibits miR-34a synthesis and stimulates antioxidant
gene expression in the aorta of diabetic mice. QPCR analysis of (E) miR-34a, (F) SIRT1,
(G) eNOS and (H) catalase in mouse aorta. Representative western blots of (I) SIRT1
and (J) eNOS in mouse aorta. STZ: streptozotocin. n=6. *P < 0.05 vs. control group; # P
< 0.05 vs. STZ group.
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Figure 3-7 A. Kallistatin (KS) inhibits paraquat-induced superoxide formation in C.
elegans. (A) Representative images of superoxide formation in wild-type C. elegans.
n=10 worms per group. *P < 0.05 vs. control.
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Figure 3-7 B-D. Kallistatin (KS) enhances C. elegans longevity under oxidative stress.
Survival curves of (B) wild-type (N2) strain, (C) miR-34 mutant (gk437) and (D) sir-2.1
mutant (ok434). n=50 worms per group.
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The results indicate that miR-34 and sir-2.1 are essential for kallistatin-mediated C.
elegans longevity under oxidative stress. Kallistatin significantly increased C. elegans
thermo-tolerance at 35 °C. Wild-type worm survival rate was 38.9 ± 3.9% under thermal
condition, but kallistatin treatment at 1 and 5 lM markedly enhanced worm survival to
63.3 ± 4.4% and 72.1 ± 10.5%, respectively (Figure 3-7 E). However, kallistatin (1 or 5
µM) had no effect on the survival of miR-34 mutant or sir-2.1 mutant worms at 35 °C
(Figure 3-7 F&G). Similar to oxidative stress, these results confirm that kallistatin
promotes C. elegans survival under heat stress via regulating miR-34 and sir-2.1.
Moreover, kallistatin treatment inhibited miR-34, but increased sir-2.1 and sod-3
(MnSOD analogue) synthesis (Figure 3-7 H–J). Likewise, SOD-3 protein levels were
elevated by kallistatin treatment, as evidenced using SOD-3::GFP co-expression C.
elegans as a sod-3 indicator (Figure 3-7 K). Collectively, kallistatin inhibits miR-34
synthesis and stimulates sir-2.1 and sod-3 levels in C. elegans, and the regulatory
mechanisms parallel those observed in cultured EPCs and in aortas of diabetic mice.
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Figure 3-7 E-G. Kallistatin (KS) enhances C. elegans survival under heat stress.
Average survival ratios of (E) wild-type (N2), (F) miR-34a mutant (gk437) and (G) sir-2.1
mutant (ok434). n=30 worms per group. *P < 0.05 vs. control.
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Figure 3-7 H-K. Kallistatin inhibits miR-34 but stimulates sir-2.1 and sod-3 expression
in C. elegans. QPCR analysis of (H) miR-34, (I) sir-2.1, (J) sod-3 mRNA levels. (K)
Representative images of SOD3 expression in SOD-3::GFP C. elegans. n=100 worms
per group. *P < 0.05 vs. control.
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Figure 3-8. Signaling mechanism by which kallistatin inhibits vascular senescence and
aging. Kallistatin via its heparin-binding site antagonizes TNF-α mediated miR-21
synthesis, ROS formation, PAI-1 and p16INK4a expression, and telomerase activity in
EPCs. Kallistatin via its active site prevents miR‐34a‐mediated inhibition of antioxidant
genes SIRT1, eNOS, and catalase and SOD-3. The tyrosine kinase inhibitor, genistein,
blocks kallistatin's ability to modulate miR-34a and antioxidant gene expression.

61

Discussion
This study demonstrates a novel role of kallistatin in vascular senescence and
aging using cultured EPCs, STZ-induced diabetic mice, and C. elegans. Recombinant
human kallistatin treatment significantly reduced EPC senescence by blocking TNF-αinduced oxidative stress, and decreased the senescence markers, PAI-1, miR-21, and
p16INK4a, but increased telomerase activity. Kallistatin via its active site inhibited miR34a and stimulated SIRT1, eNOS, and catalase synthesis, whereas overexpression of
miR-34a abolished kallistatin’s effects on these antioxidant enzymes and antisenescence action. Moreover, kallistatin suppressed miR-34a and stimulated SIRT1 and
eNOS expression, through interaction with cell surface tyrosine kinase in EPCs.
Likewise, kallistatin administration in STZ-induced diabetic mice alleviated aortic
senescence and oxidative stress associated with reduced miR-34a and miR-21
synthesis and increased SIRT1, eNOS, and catalase levels. Moreover, kallistatin
prolonged wild-type C. elegans lifespan under heat or oxidative stress conditions by
inhibiting miR-34, and stimulating sir-2.1 (SIRT1). These in vitro and in vivo studies
support the view that kallistatin protects against vascular senescence and aging by
preventing miR-34a-mediated inhibition of SIRT1 and eNOS, thus inhibiting oxidative
stress. The signaling mechanisms of kallistatin’s anti-senescence actions are depicted in
Figure 3-8.

Oxidative stress is the leading cause of endothelial dysfunction and senescence.
The inflammatory factor TNF-α has the ability to potentiate ROS generation by activating
NADPH oxidase on the endothelial cell surface (Yoshida & Tsunawaki, 2008).
Conversely, eNOS reduces intracellular superoxide levels through NO formation, which
inhibits NADPH oxidase activity (Fujii et al., 1997). In this study, we demonstrated that
kallistatin inhibited TNF-α-induced oxidative stress via activation of the PI3K-Akt-eNOS
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signaling pathway, as kallistatin’s effect was blocked by LY294002 and L-NAME.
Likewise, our previous report showed that kallistatin antagonized TNF-α-mediated
apoptosis through increased Akt-eNOS phosphorylation in endothelial cells (Shen et al.,
2010). Kallistatin also promoted the proliferation and migration of EPCs via activation of
Akt-eNOS signaling pathway (Gao et al., 2014). Thus, it is likely that kallistatin
antagonizes TNF-α-induced senescence by activation of Akt and eNOS phosphorylation
in EPCs. In addition, miR-21 modulates ROS production in several cell types (Zhang et
al., 2012, Jiang et al., 2014), and kallistatin inhibited TGF-β induced miR-21 synthesis
and oxidative stress in endothelial cells (Guo et al., 2015). Our current data showed that
kallistatin also blocked TNF-α-mediated miR-21 expression and ROS production in
EPCs. Kallistatin’s vasoprotective effect has been shown in animal models of saltinduced hypertension, renal injury, and chronic myocardial infarction through inhibiting
oxidative stress (Gao et al., 2008; Shen et al., 2008, 2010). Consistently, our current
study showed that kallistatin attenuated vascular aging and oxidative stress in
conjunction with increased antioxidant protein levels in the aortas of STZ-induced
diabetic mice. Collectively, these studies indicate that kallistatin, via inhibiting oxidative
stress, protects against vascular senescence.

The longevity factor SIRT1 is a NAD+-dependent histone deacetylase, and high
levels of SIRT1 were shown to inhibit oxidative stress and DNA damage (Alcendor et al.,
2007). SIRT1 activates antioxidant enzymes, including catalase and MnSOD, by
stimulating the FOXO transcription factors (Brunet et al., 2004). Through a positive
feedback loop, SIRT1 activates eNOS, which in turn activates SIRT1 (Ota et al., 2010).
Importantly, SIRT1 is highly expressed during angiogenesis in endothelial cells, and
disrupting SIRT1 abrogates vascular endothelial homeostasis and remodeling (Potente
et al., 2007). Our results indicate that kallistatin treatment stimulated the expression of
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SIRT1 and its downstream antioxidant enzymes eNOS and catalase, as well as
antagonized TNF-α-mediated inhibition of SIRT1, eNOS, and catalase synthesis in
cultured EPCs. Similarly, kallistatin elevated the levels of these antioxidant enzymes in
the aortas of STZ-induced diabetic mice. In C. elegans, SIRT1 homolog sir-2.1 and
MnSOD homolog sod-3 were also increased upon kallistatin treatment, whereas sir-2.1
mutant abolished kallistatin mediated stress resistance. Collectively, these combined
results reveal a critical role of SIRT1 in mediating kallistatin’s effect on oxidative stress
and vascular aging.

The role of miR-34a in regulating cell senescence, differentiation, and vitality has
been extensively highlighted in a wide variety of cells (Tazawa et al., 2007, Zhao et al.,
2010). miR-34a triggers senescence partly through genetic inhibition of SIRT1 in EPCs
(Zhao et al., 2010). This observation inspired us to explore the potential role of kallistatin
in modulating miR-34a-dependent SIRT1 expression in EPCs. Our results showed that
kallistatin significantly suppressed miR-34a synthesis, but stimulated eNOS, SIRT1, and
catalase expression in EPCs and aortas of diabetic mice. Intriguingly, overexpression of
miR-34a by transfection of miR-34a mimic abolished kallistatin-induced antioxidant gene
expression. Moreover, miR-34a mimic markedly induced EPC senescence; however,
kallistatin had no effect on miR-34a-induced EPC senescence. These findings indicate
that kallistatin’s anti-senescent effect is mediated by suppressing miR-34a synthesis in
EPCs. Furthermore, genistein, a tyrosine kinase inhibitor, blocked kallistatin’s effects on
the expression of miR-34a, eNOS, and SIRT1, which is partially in consistent with our
previous findings in human endothelial cells (Guo et al., 2015). The results reveal that
kallistatin, through interacting with tyrosine kinase, downregulates miR-34a leading to
vascular senescence attenuation.
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Kallistatin via its two structural elements regulates differential signaling pathways
(Chao et al., 2016). Kallistatin via its heparin-binding site antagonized TNF-α-induced
NF-κB activation and thus inflammatory gene expression (Yin et al., 2010). Our current
finding indicates that kallistatin also antagonized TNF-α-induced senescence and
oxidative stress in EPCs. Kallistatin blocks TNF-α-induced endothelial senescence
mediators, miR-21 and p16INK4a. Likewise, kallistatin markedly downregulated TNF-αinduced expression of PAI-1, a pro-atherogenic factor and an endothelial aging marker.
Furthermore, kallistatin reversed TNF-α-mediated inhibition of telomerase, which is
responsible for maintaining telomere length and cellular integrity. Consistently, our
recent report showed that circulatory kallistatin levels are positively associated with
leukocyte telomere length in humans (Zhu et al., 2016), indicating a potential role of
kallistatin in maintaining telomere length. Therefore, kallistatin via its heparin-binding site
blocks TNF-α-mediated effects in EPCs. Meanwhile, kallistatin’s active site is essential
for stimulating eNOS and SIRT1 in endothelial cells (Guo et al., 2015). In this study, we
showed that kallistatin through its active site inhibited miR-34a synthesis and stimulated
eNOS and SITR1 expression in EPCs. Therefore, kallistatin, through its two functional
domains, displays anti-senescence actions by blocking TNF-α-induced effects, and
preventing miR-34amediated inhibition of SIRT1 and eNOS.

The STZ-induced diabetic mouse is a popular model for studying vascular injury
and aging. Kallistatin levels are markedly reduced in vitreous fluids of patients with
diabetic retinopathy and in the retinas in STZ-induced diabetic rats (Ma et al., 1996,
Hatcher et al., 1997). Decreased kallistatin levels are also observed in the kidney of
STZ-induced diabetic mice and in TNF-α-induced senescent human EPCs. Moreover,
endogenous kallistatin plays a protective role in multi-organ function, as depletion of
kallistatin by neutralizing antibody injection augmented cardiovascular and renal
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damage, and increased oxidative stress, inflammation, and endothelial cell loss in
hypertensive rats (Liu et al., 2012). Furthermore, kallistatin treatment exerts
renoprotective effects in diabetic nephropathy by suppressing ROS and inflammatory
gene expression in mice (Yiu et al., 2016). Accumulating evidence indicates that
kallistatin acts as a potent antioxidant and anti-inflammatory agent in cultured cells and
animal models (Gao et al., 2008; Shen et al., 2010; Yin et al., 2010; Li et al., 2014; Guo
et al., 2015). As oxidative endothelial injury and aging are observed in diabetes,
kallistatin may have a role in protection against vascular damage in diabetic disease.
Indeed, our current study showed that kallistatin treatment in STZ-induced diabetic mice
attenuated aortic senescence and superoxide formation, in association with reduced
miR-34a and miR-21, and increased SIRT1, eNOS, and catalase synthesis. The findings
in diabetic mice support the concept that kallistatin plays a protective role in vascular
injury and aging by regulating miR-34a, SIRT1, and eNOS synthesis.

C. elegans is a prominent model for aging study, as pathways mediating
longevity and metabolism are conserved from C. elegans to mammals. Heat or oxidative
stress induces elevated levels of ROS and cellular damage in C. elegans, leading to
accelerated aging (Rodriguez et al., 2013). In this study, we demonstrated that kallistatin
treatment improved C. elegans lifespan or survival under oxidative stress or heat
conditions. Previous studies showed that miR-34 loss-offunction mutation or sir-2.1
(SIRT1 homolog) overexpression in C. elegans markedly delayed the age-related
physiological decline and prolonged lifespan in response to stress conditions
(Tissenbaum & Guarente, 2001, Yang et al., 2013). Herein, we showed that kallistatin
treatment inhibited miR-34 and stimulated sir-2.1 and sod-3 synthesis in wild-type C.
elegans. Kallistatin’s protective effect in the longevity of wild-type C. elegans was
abolished in miR-34 or sir-2.1 mutant C. elegans under stress conditions. Consistent
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with the findings in EPCs and diabetic mice, these results further verify that kallistatin’s
anti-aging effect is dependent on miR-34 inhibition and sir-2.1 (SIRT1) activation.
Collectively, these findings provide significant insights regarding the mechanism of
kallistatin in regulating the aging process via miR-34a-SIRT1 pathway.

In conclusion, this is the first study to demonstrate the protective role of kallistatin
in vascular senescence and aging. Kallistatin’s anti-aging effect is mainly attributed to
suppression of oxidative stress by preventing miR-34a-mediated inhibition of antioxidant
gene expression. This study established an essential role of kallistatin’s active site in the
regulation of miR-34a, SIRT1, and eNOS synthesis by interaction with a tyrosine kinase.
As kallistatin is an endogenous protein, minimal side effects are expected with kallistatin
treatment. Therefore, this study opens a new prospective in kallistatin-based therapeutic
intervention in age-associated cardiovascular diseases.
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CHAPTER IV

TO DETERMINE THE ROLE OF ENDOGENOUS KALLISTATIN IN
ENDOTHELIAL SENESCENCE, VASCULAR AND ORGAN INJURY
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Summary
This study is aimed to further investigate the role and mechanism of endogenous
kallistatin in endothelial senescence, vascular and organ injury. Kallistatin treatment
inhibited H2O2-induced senescence in human endothelial cells, as indicated by reduced
senescence-associated-β-galactosidase activity, p16INK4a and plasminogen activator
inhibitor-1 expression, and elevated telomerase activity. Kallistatin blocked H2O2-induced
superoxide formation, NADPH oxidase levels, and VCAM-1, ICAM-1, IL-6, and miR-34a
synthesis. Kallistatin reversed H2O2-mediated inhibition of eNOS, SIRT1, catalase and
superoxide dismutase (SOD)-2 expression, and directly stimulated these genes.
Moreover, kallistatin’s anti-senescence and antioxidant effects were attributed to SIRT1mediated eNOS pathway. Kallistatin, via interaction with tyrosine kinase, upregulated
Let-7g, whereas Let-7g inhibitor abolished kallistatin’s effects on miR-34a and
SIRT1/eNOS synthesis, leading to inhibition of senescence, oxidative stress and
inflammation. Furthermore, lung endothelial cells isolated from endothelium-specific
kallistatin knockout mice displayed marked reduction of mouse kallistatin expression.
Kallistatin deficiency in mouse endothelial cells exacerbated senescence, oxidative
stress and inflammation compared to wild-type mouse endothelial cells, and H2O2
treatment further magnified these effects. Kallistatin deficiency caused marked reduction
of Let-7g, SIRT1, eNOS, catalase and SOD-1 mRNA levels, and elevated miR-34a
synthesis in mouse endothelial cells. Moreover, systemic depletion of kallistatin resulted
in worsened aortic oxidative stress and renal injury and fibrosis in general kallistatin
knockout mice with diabetes. These findings indicate that endogenous kallistatin protects
against endothelial senescence, vascular and organ injury and kallistatin treatment
reduces endothelial senescence by modulating Let-7g-mediated miR-34a-SIRT1-eNOS
pathway.
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Introduction
Endothelial senescence contributes to the onset and development of vascular
injury and age-associated vascular diseases, such as atherosclerosis, diabetes, and
coronary artery diseases (Minamino et al., 2004, Minamino & Komuro, 2007). Vascular
senescence gives rise to the alteration of morphological features and functional
physiology in blood vessels (Cavallaro et al., 2000). The key features of senescent cells
are: permanent growth arrest state, flattened morphology, elevation of SA-β-gal activity,
cell cycle inhibitor p16INK4a expression, and endothelial dysfunction marker plasminogen
activator inhibitor-1 (PAI-1) expression. Moreover, cellular senescence is characterized
by shortened telomere length or reduced telomerase activity (Hornsby, 2007). Oxidative
stress and inflammation have been implicated in the aging process and adversely affect
endothelial availability and function (Freund et al., 2010, Bhayadia et al., 2016).
Oxidative stress compromises telomere integrity and nitric oxide (NO) bioavailability to
accelerate cellular senescence in endothelial cells (Kurz et al., 2004). Vascular
senescence is also associated with enhanced expression of the inflammatory molecules,
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1
(ICAM-1), which leads to augmented adhesion of monocytes into vascular wall,
facilitating the ignition and progression of aging-associated vascular diseases (Gorgoulis
et al., 2005, Powter et al., 2015). Therefore, inhibition of oxidative stress and
inflammation is of great significance for controlling endothelial senescence.

miRNAs are essential regulators for a plethora of cellular processes. A highly
evolutionarily conserved miRNA Let-7g has been reported to inhibit oxLDL-induced
apoptosis of endothelial cells and alleviate atherosclerosis in mice (Zhang et al., 2013,
Liu et al., 2017). Let-7g also has the ability to improve multiple endothelial functions by
stimulating SIRT1 signaling (Liao et al., 2014). Furthermore, miR-34a, a well-recognized
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tumor suppressor and a senescent inducer, triggers endothelial senescence by directly
suppressing the target gene SIRT1 (Ito et al., 2010). SIRT1, an NAD+-dependent
deacetylase and anti-aging molecule, is decreased in vascular tissue undergoing
senescence. Evidence has indicated a positive feedback regulation between SIRT1 and
eNOS. SIRT1 promotes the expression of eNOS and activates eNOS by its deacetylase
activity,

while

eNOS

through

NO

production

stimulates

SIRT1

expression

(Mattagajasingh et al., 2007, Potente & Dimmeler, 2008, Xia et al., 2013). NO produced
from eNOS has a wide range of biological properties to maintain vascular homeostasis,
including vascular dilation, and inhibition of oxidative stress and inflammation. Therefore,
Let-7g, miR-34a, and antioxidant genes SIRT1 and eNOS are key signaling molecules
for regulating endothelial senescence.

Recently plasma kallistatin levels have been shown to be positively associated
with leukocyte telomere length in young African Americans, implicating the involvement
of kallistatin in anti-aging process (Zhu et al., 2016). Moreover, kallistatin depletion by
neutralizing antibody injection worsens cardiovascular and renal injury, oxidative stress
and inflammation in hypertensive rats (Liu et al., 2011), indicating endogenous kallistatin
may have a role in vascular and organ injury. H2O2 is widely used to achieve oxidative
stress-induced premature senescence in endothelial cells and fibroblasts (Chen J. H. et
al., 2007, Liu D. H. et al., 2012). According to previous findings, the dose of H2O2 (100
µM) represents subcytotoxic conditions to induce senescence (Frippiat et al., 2001, Li R.
L. et al., 2016). In this study, we further investigated the role and mechanism of
kallistatin in oxidative stress-induced endothelial senescence by 1) exogenous kallistatin
treatment in human endothelial cells, and 2) endogenous kallistatin deficiency in mouse
lung endothelial cells isolated from endothelium-specific kallistatin-deficient (KSendo-/-)
mice. General kallistatin knockout (KS-/-) mice were also generated and subjected to
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streptozotocin (STZ) challenge, which is a chemical agent to induce diabetes by
damaging islet β-cells. We further determined the role of endogenous kallistatin in
diabetes-induced vascular and organ injury.
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Material and Methods
Human Endothelial Cell Culture and Treatments
Human umbilical vein endothelial cells (HUVECs) were cultured as previously
described in Chapter II. HUVECs at 80% confluency were pre-treated with kallistatin (1
µM) followed by hydrogen peroxide (H2O2, 100 µM; Fisher Scientific) challenge for 3
days in serum-free EBM-2 medium; senescent markers and oxidative stress indicators
were evaluated. To measure gene expression, HUVECs were pre-incubated with
kallistatin (1 µM) followed by H2O2 (100 µM) treated for 24 h. To determine the causal
relationship of SIRT1 and eNOS, HUVECs were pre-treated with SIRT1 inhibitor
nicotinamide (NAM, 5 mM; Sigma) or NOS inhibitor Nω-nitro-L-arginine methyl ester
hydrochloride (L-NAME, 100 µM; Sigma) for 30 min, followed by kallistatin (1 µM) and
H2O2 (100 µM) treatment for 24 h. Similarly, cultured primary mouse lung endothelial
cells at 80% confluency were treated with or without H2O2 (100 µM) for 3 days to
evaluate senescent markers and oxidative stress indicators, and for 24 h to measure
gene expression

SA-β-gal Staining
Cellular senescence of HUVECs or mouse lung endothelial cells in 12-well plates
was determined with SA-β-gal staining kit (Cell Signaling).

Telomerase Activity Assay
Telomerase activity was measured using TRAPEZE RT telomerase detection kit
(EMD Millipore).

NADPH Oxidase Activity Assay
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The enzymatic activity of NADPH oxidase was assessed by a luminescence
assay in the presence of lucigenin (250 µM; Sigma) and NADPH (100 µM; Sigma).

Detection of Superoxide Formation
HUVECs superoxide generation was detected using the fluorescent probe 2’, 7’dichlorodihydrofluorescein diacetate (DCFH-DA; 10 μM, Sigma). Superoxide levels in
mouse lung endothelial cells and mouse thoracic aortas were determined by fluorescent
probe dihydroethidium (DHE; 3 µM, Sigma).

miRNA Transfection
HUVECs were grown in antibiotic-free EBM-2 on plates for 24 h, and then
transfected with Let-7g inhibitor (10 pM, antisense RNA Let-7g), miR-34a mimic or
control miRNA (10 pM; Life Technologies) with Lipofectamine RNAiMAX reagent (Life
Technologies) according to the manufacturer's protocol.

Quantitation of mRNA by qRT-PCR
RNA extraction, reverse transcription and Real-time PCR were performed as
previously described in Chapter II method section. The following primers were used:
human 18S, p16INK4a, eNOS, SIRT1, catalase, PAI-1, NADPH oxidase 4 and miR-34a;
mouse GAPDH, eNOS, SIRT1, catalase and miR-34a as described in Chaper III.
Superoxide

dismutase

(SOD)-2

(Hs00167309_ml),

ICAM-1

(Hs00277001_ml),

interleukin (IL)-6 (Hs00174131_ml), VCAM-1 (Hs00365486_ml), Let-7g (002282), mouse
SOD-1

(Mm01344233_gl),

mouse

VCAM1

(Mm01320970_ml),

(Mm00446190_ml),

mouse

ICAM-1

(Mm00516024_gl),

(Mm00434669_ml),

mouse

PAI-1

(Mm00435858_ml),
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mouse

mouse
mouse

IL-6

kallistatin
p16INK4a

(Mm00494449_ml). Data were analyzed with 2−ΔΔCt value calculation using control genes
for normalization.

Western Blot
Lysed cell sample were lysed, separated and immunobloted as previously
described in Chapter II. Primary antibodies were anti-SIRT1, anti-eNOS, anti-mouse
kallistatin, anti-β-actin, anti-Tie2, anti-fibronectin, anti-α-SMA and anti-α-tubulin (Cell
Signaling).

Generation of Endothelium-Specific Kallistatin Knockout Mice
Heterozygous kallistatin floxing mice in C57/BL6 strain (male and female, KSfl/+)
were obtained from Biocytogen, LLC (Worcester), and male wild-type C57/BL6 mice (7-8
weeks of age) were purchased from Harlan (Indianapolis). These mice were housed in a
germ-free environment. All procedures complied with the standard for care and use of
animal subjects as stated in the Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Resources, National Academy of Sciences). KSfl/+ mice were
inbred to produce homozygous floxed kallistatin mice (KSfl/fl). To generate endotheliumspecific heterozygous kallistatin knockout mice (Tie2Cre+KSfl/+), female KSfl/fl mice were
crossed with male Tie2-Cre mice (The Jackson Laboratories). Tie2Cre+KSfl/+ mice were
then crossed with KSfl/fl mice to generate endothelium-specific kallistatin knockout
(KSendo-/-) mice. The expression of mouse kallistatin null allele in endothelium of KSendo-/mice was determined by PCR with a pair of custom primers: 5’-TCA AGT CCC TCA TGT
GCG TTG GTA G-3’, and 5’-ATG TCA ATC ACA ATG CCC TCT GCC T-3’. The
amplification conditions are 95°C for 5 min and 35 cycles of 95°C for 30 s, 63°C for 30 s,
and 72°C for 1 min, followed by a 10-min incubation at 72°C at the end of the run.
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Amplification products were resolved on a 3% agarose gel. Mouse kallistatin deficiency
in isolated mouse lung endothelial cells was verified by qRT-PCR and western blot.

Isolation and Identification of Mouse Lung Endothelial Cells
Mouse lung endothelial cells were isolated from 8-week-old KSendo-/- and WT mice
as described (Alphonse et al., 2015). Mice were euthanized by CO2 inhalation followed
by cervical dislocation. The lungs were digested with 0.1% collagenase in PBS for 45
min. The cell suspension was isolated by magnetic immunoselection with CD31conjugated magnetic beads (Miltenyi Biotec) using the magnetic-activated cell sorting
system (MACS, Miltenyi Biotec). Purified mouse lung endothelial cells were cultured on
gelatin-coated tissue culture dishes with EBM-2 medium with 10% FBS and 1%
antibiotics until they became confluent. Newly grown colonies were digested, incubated
with CD31 magnetic beads and selected through MACS again. After the second
selection, mouse lung endothelial cells were seeded in a T75 flask provided with
complete EBM-2 medium to grow robustly. Mouse endothelial cells were characterized
with endothelial marker CD31 by PCR and immunostaining. For immunostaining, mouse
endothelial cells were fixed with 4% paraformaldehyde, incubated with blocking buffer,
and followed with rat anti-mouse CD31 antibody (Santa Cruz Biotechnology) overnight at
4°C. After washing with PBS, cells were incubated with anti-rat FITC secondary antibody
(Sigma) for 1 h at room temperature, washed with PBS, and counterstained with
Hoechst 33342 (1 µg/ml; Sigma).

Generation and Identification of General Kallistatin Knockout Mice
To generate heterozygous kallistatin knockout mice (CAGCre+KSfl/+), female
KSfl/fl mice were crossed with male CAG-Cre mice (The Jackson Laboratories).
CAGCre+KSfl/+ mice were then crossed with KSfl/fl mice to produce CAGCre+KSfl/fl mice.
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Mice at the age of 4-5 week-old were subcutaneously injected with tamoxifen (75mg/kg,
dissolved in corn oil) for 5 days to induce Cre recombinase activity. Genotyping were
performed after one week of tamoxifen induction using 0.5 cm tail biopsy. Serpina3cA1Loxp-F 5’-CTG CTC ATG ATG TAG GAG ATC TTA GC-3’, Serpina3c-A1Loxp-R 5’TCC AGT CAT GGT TTG GAT AGT GG-3’; Cre-F: 5’-GCG GTC TGG CAG TAA AAA
CTA TC-3’, Cre-R: 5’-GTG AAA CAG CAT TGC TGT CAC TT-3’. The amplification
conditions are described as above. Mouse kallistatin ablation was also verified by
western blot.

Diabetes Model
Male KS-/- mice and WT littermates (12 weeks of age) were subjected to 6-day
continuous intraperitoneal injections of STZ (60 mg/kg; Sigma). Sodium citrate buffer
(0.1 M, pH 4.5) was injected in control animals. Mice with blood glucose > 250 mg/dL
were considered diabetic. A total of 24 mice were randomly assigned to three groups:
WT group (n = 6), KS-/- group, WT+STZ group (n = 6), and KS-/- +STZ group (n = 6). Two
months after blood glucose stabilization, thoracic aortas and kidney samples were
collected for histological analysis or western blot analysis.

Morphological Investigations
5 µm-thick renal sections and 8 µm-thick aortic sections were obtained from each
sample. Renal sections were stained with Sirius red to determine the extent of fibrosis.
Artery sections were stained with dihydroethidium (DHE; Signma) at 37°C for superoxide
determination. Primary antibodies for VE-cadherin, CD31 and α-SMA were used to
detect in HUVECs with fluorescence microscopy. Briefly, cells were fixed with 4%
paraformaldehyde and permeabilized with 0.2% Triton X-100, and blocked with 3% BSA
in PBS for 1 h at room temperature, followed by incubation with primary antibody
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overnight at 4°C. After incubation, cells were rinsed three times with PBS and incubated
with fluorochrome-conjugated secondary antibody for 2 h at room temperature in the
dark. Cells were then washed with PBS and counter stained with Hoechst 33342 (5
µg/ml; Cell Signaling Technology) for 5 min. Plates were then observed under a
fluorescence microscope.

Assays for Plasma Creatinine and Blood Urea Nitrogen (BUN) Levels
Plasma was collected from each sample. Protein levels in plasma were
measured by Pierce BCA protein assay kit (Thermo Fisher Scientific). Plasma creatinine
or BUN levels were determined using Quantichrom creatinine assay kit (DITC500) or
Quantichrom urea assay kit (DIUR-500) (BioAssay Systems).

Statistical Analysis
Data are presented as mean ± S.E.M. Statistical analyses were performed with
GraphPad Prism 7 (GraphPad Software). ANOVA and Student’s t-test analysis were
used to assess differences between data means as appropriate. A value of P < 0.05 was
considered statistically significant.
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Results
Kallistatin Attenuates H2O2-Induced Cellular Senescence in Human Endothelial
Cells
Representative images showed that H2O2 treatment induced pronounced cellular
senescence in HUVECs, characterized by increased senescent marker SA-β-gal activity
compared with the control group, while purified recombinant human kallistatin
pretreatment reversed the effect (Figure 4-1 A). Quantitative analysis of positive SA-βgal staining cells confirmed the results (Figure 4-1 B). Senescent markers p16INK4A, PAI1 and telomerase were also evaluated. Kallistatin blocked H2O2-induced p16INK4A and
PAI-1 expression, and prevented H2O2-mediated inhibition of telomerase activity (Figure
4-1 C-E). Therefore, kallistatin is capable of blocking oxidative stress-induced
endothelial senescence.

Kallistatin Inhibits H2O2-Induced Oxidative Stress and Inflammation
Representative

images

showed

that

kallistatin

attenuated

H2O2-induced

superoxide formation in human endothelial cells, which was verified by quantitative
analysis (Figure 4-2 A&B). Similarly, kallistatin antagonized H2O2-induced NADPH
oxidase activity and NADPH oxidase 4 mRNA levels (Figure 4-2 C&D). Moreover,
kallistatin inhibited H2O2-mediated expression of the pro-inflammatory genes VCAM-1,
ICAM-1 and IL-6 (Figure 4-2 E-G). Kallistatin alone inhibited miR-34a, and prevented
H2O2-induced miR-34a synthesis (Figure 4-2 H). These results indicate that kallistatin
inhibits H2O2-induced oxidative stress and inflammation in endothelial cells.

Kallistatin Inhibits Endothelial Senescence and Oxidative Stress through SIRT1Mediated eNOS Pathway
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Figure 4-1. Kallistatin (KS) alleviates H2O2-induced endothelial senescence in human
endothelial cells. (A) Representative images of SA-β-gal staining. (B) Quantification
analysis of positive SA-β-gal staining cells. (C) QPC analysis of p16INK4a. (D) QPCR
analysis of PAI-1 mRNA levels. (E) Telomerase activity determined by QPCR (C-D).
n=3. *P < 0.05 vs. control, #P < 0.05 vs. H2O2 group.
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Figure 4-2 A-D. Kallistatin (KS) suppresses H2O2-induced oxidative stress in human
endothelial cells. (A) Representative images of superoxide formation determined by
fluorescence dye oxidized DCF. (B) Quantitative analysis of fluorescent counts. (C)
QPCR analysis of NADPH oxidase 4 mRNA levels. (D) NADPH oxidase activity
determined by lucigenin chemiluminescence assay. n=3. *P < 0.05 vs. control, #P < 0.05
vs. H2O2 group.
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Figure 4-2 E-H. Kallistatin (KS) suppresses H2O2-induced inflammation and miR-34a
synthesis in human endothelial cells. QPCR analysis of (A) VCAM-1, (B) ICAM-1, (C) IL6 and (D) miR-34a RNA levels. n=3. *P<0.05 vs. control, #P<0.05 vs. H2O2 group.
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In order to determine whether the kallistatin-mediated protection against
endothelial senescence is associated with antioxidant gene regulation, the effects of
kallistatin on the regulation of SIRT1, eNOS, catalase and SOD-2 were determined.
Kallistatin treatment not only markedly enhanced SIRT1, eNOS, catalase and SOD-2
expression, but also prevented H2O2-mediated inhibition of these antioxidant genes
(Figure 4-3 A-D). Moreover, NAM, a potent inhibitor of SIRT1 activity, blocked kallistatinstimulated eNOS expression, whereas L-NAME, an NOS inhibitor, had no effect on
kallistatin-stimulated SIRT1 expression (Figure 4-3 E&F), indicating that kallistatin via
SIRT1 elevation stimulates eNOS. Furthermore, NAM abolished kallistatin’s antioxidant
activity and anti-senescent action, as evidenced by reversing kallistatin’s inhibition of
SA-β-gal activity and NADPH oxidase activity in HUVECs (Figure 4-3 G&H). These
results indicate that the SIRT1-mediated eNOS pathway plays a crucial role in
kallistatin’s inhibition of endothelial senescence and oxidative stress.

Kallistatin by Let-7g Upregulation Blocks miR-34a-Mediated Inhibition of SIRT1eNOS Pathway, and Reduces Endothelial Senescence, Oxidative Stress and
Inflammation
To illustrate whether kallistatin-mediated inhibition of endothelial senescence was
associated with upregulation of Let-7g, the effect of kallistatin on Let-7g expression was
determined. Kallistatin treatment significantly increased Let-7g synthesis, whereas
genistein, a tyrosine kinase inhibitor, blocked kallistatin’s effect (Figure 4-4 A),
implicating that kallistatin interacts with a cell surface tyrosine kinase to stimulate Let-7g
synthesis. Let-7g inhibitor (Let-7g anti-sense RNA) blocked kallistatin’s inhibition of miR34a synthesis (Figure 4-4 B), indicating that kallistatin regulates Let-7g-mediated miR34a pathway. Conversely, miR-34a mimic had no effect on kallistatin-induced Let-7g
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D

Figure 4-3 A-D. Kallistatin (KS) stimulates antioxidant gene expression and prevents
H2O2-mediated inhibition of these genes in human endothelial cells. QPCR analysis of
(A) SIRT1, (B) eNOS, (C) catalase and (D) SOD-2 mRNA levels. n=3. *P < 0.05 vs.
control, #P < 0.05 vs. H2O2 group.
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Figure 4-3 E-H. Kallistatin (KS) inhibits H2O2-induced senescence and oxidative stress
through SIRT1-eNOS pathway in human endothelial cells. QPCR analysis of (E) eNOS
and (F) SIRT1 mRNA levels. (G) Quantification analysis of SA-β-gal positive staining
cells. (H) NADPH oxidase activity determined by lucigenin chemiluminescence. n=3. *P
< 0.05 vs. control, #P < 0.05 vs. KS group or H2O2 group.
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Figure 4-4 A-E. Kallistatin (KS) through Let-7g to inhibit miR-34a and elevate SIRT1 and
eNOS synthesis in human endothelial cells. QPCR analysis of (A) Let-7g, (B) miR-34a,
(C) Let-7g, (D) SIRT1 and (E) eNOS mRNA levels. GEN: genistein, a tyrosine kinase
inhibitor; Let-7g I: Let-7g inhibitor. n=3. *P < 0.05 vs. control, #P < 0.05 vs. KS group or
H2O2 group.
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expression (Figure 4-4 C), thus kallistatin’s effect on Let-7g upregulation is independent
of miR-34a. Moreover, Let-7g inhibitor abolished kallistatin-induced SIRT1 and eNOS
mRNA levels, and blocked kallistatin-mediated elevation of SIRT1 and eNOS levels by
western blot (Figure 4-4 D-F), indicating an essential role of Let-7g in kallistatin’s
induction of antioxidant genes. Furthermore, Let-7g inhibitor abolished kallistatin’s
inhibitory effect on H2O2-induced senescence, characterized by elevated p16INK4a and
PAI-1 mRNA levels in endothelial cells (Figure 4-4 G&H). Likewise, Let-7g inhibitor
blocked kallistatin’s effect on H2O2-induced NADPH oxidase activity and VCAM-1
expression (Figure 4-4 I&J). These combined findings indicate that kallistatin, by
interacting with a tyrosine kinase, upregulates Let-7g, thus inhibiting miR-34a-SIRT1eNOS pathway. Therefore, Let-7g plays a crucial role in mediating kallistatin’s inhibitory
effects on endothelial senescence.

Identification of Kallistatin Deficiency in Mouse Lung Endothelial Cells
We generated endothelium-specific kallistatin knockout (KSendo-/-) mice by
crossing KSfl/fl mice with Tie2Cre+KSfl/+ mice. Lung endothelial cells were isolated from
WT mice and KSendo-/- mice. Cultured primary mouse lung endothelial cells were
identified by CD31 expression and immunostaining (Figure 4-5 A&B). In lysed mouse
endothelial cell DNA samples, kallistatin null allele (del) was detected only in KSendo-/mice, but not in WT mice (Figure 4-5 C), indicating that endogenous kallistatin is ablated
in mouse endothelial cells. Moreover, the protein and mRNA levels of mouse kallistatin
were markedly diminished in endothelial cells from KSendo-/- mice, compared with
endothelial cells from WT mice (Figure 4-5 D&E). These results confirm that mouse
endogenous kallistatin is deficient in KSendo-/- mouse endothelial cells.
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Figure 4-4 F-J. Kallistatin through Let-7g induction stimulates SIRT1 and eNOS, and
inhibits endothelial senescence, oxidative stress and inflammation. (F) Representative
western blot of SIRT1 and eNOS and quantification. QPCR of (G) p16INK4a and (H) PAI1. (I) Chemiluminescence analysis of NADPH oxidase activity. (J) QPCR analysis of
VCAM-1. Let-7g I: Let-7g inhibitor. n=3. *P < 0.05 vs. control, #P < 0.05 vs. KS group or
H2O2 group.
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mouse KS
α-tubulin

Figure 4-5. Identification of kallistatin (KS) deficiency in isolated mouse lung endothelial
cells. (A) Representative images of immunostaining of endothelial marker CD31
expression in mouse lung endothelial cells. (B) CD31 expression determined by PCR.
(C) Identification of mouse kallistatin depletion (del) by target null gene DNA
electrophoresis. (D) Representative immunoblots of mouse KS protein. (E) QPCR
analysis of mouse kallistatin mRNA levels. n=3. *P < 0.05 vs. control.
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Kallistatin Deficiency Aggravates Oxidative Stress-Induced Senescence, Oxidative
Stress and Inflammation in Mouse Endothelial Cells
Cultured primary mouse lung endothelial cells with or without H2O2 treatment
were used to determine the effect of kallistatin deficiency on endothelial senescence,
oxidative stress and inflammation. In the non-H2O2-treated groups, kallistatin-deficient
endothelial cells displayed increased SA-β-gal activity, p16INK4a and PAI-1 expression,
compared to WT mouse endothelial cells (Figure 4-6 A-C). Mouse kallistatin deficiency
in H2O2–treated endothelial cells further enhanced the levels of senescence makers,
compared to H2O2–treated WT mouse endothelial cells (Figure 4-6 A-C). Moreover,
cellular superoxide formation and NADPH oxidase activity were increased upon H2O2
treatment, and kallistatin deficiency further enhanced superoxide formation and NADPH
oxidase activity (Figure 4-6 D&E). Likewise, kallistatin deficiency increased H2O2induced VCAM-1, ICAM-1 and IL-6 mRNA levels in kallistatin-deficient endothelial cells
(Figure 4-6 F-H). Therefore, kallistatin deficiency in mouse endothelial cells exacerbates
endothelial senescence, oxidative stress and inflammation. These findings implicate a
protective role of endogenous kallistatin in stress-induced endothelial senescence.

Kallistatin Deficiency Reduces Let-7g and Antioxidant Gene Expression and
Increases miR-34a Synthesis in Mouse Endothelial Cells
Kallistatin deficiency in KSendo-/- mouse endothelial cells caused a significant
reduction of Let-7g, SIRT1, eNOS, catalase and SOD-1 expression compared with WT
mouse cells (Figure 4-7 A-E). Moreover, H2O2 treatment reduced the expression of Let7g and antioxidant genes in endothelial cells from WT mice, and kallistatin deficiency
further reduced the expression of these genes (Figure 4-7 A-E). Conversely, kallistatin
deficiency increased miR-34a synthesis in mouse lung endothelial cells, compared with
WT endothelial cells, with or without H2O2 treatment (Figure 4-7 F). These results
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Figure 4-6 A-E. Kallistatin (KS) deficiency in mouse lung endothelial cells increases
senescence and oxidative stress. (A) Quantitative analysis of SA-β-gal activity. QPCR
analysis of (B) p16INK4a and (C) PAI-1 mRNA levels. (D) Superoxide formation
determined by oxidized DCF fluorescent probe. (E) NADPH oxidative activity determined
by lucigenin chemiluminescence. *P < 0.05 vs. WT control group, #P < 0.05 vs. WT H2O2
group.
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Figure 4-6 F-H. Kallistatin (KS) deficiency in mouse lung endothelial cells exacerbates
inflammatory gene expression. QPCR analysis of (F) VCAM-1, (G) ICAM-1 and (H) IL-6
mRNA levels. n=3. *P < 0.05 vs. WT control group, #P < 0.05 vs. WT H2O2 group.
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Figure 4-7. Kallistatin (KS) deficiency inhibits the synthesis of Let-7g and antioxidant
genes and elevates miR-34a in mouse lung endothelial cells. QPCR analysis of (A) Let7g, (B) SIRT1, (C) eNOS, (D) catalase, (E) SOD1 and (F) miR-34a. n=3. *P < 0.05 vs.
WT control group, #P < 0.05 vs. WT H2O2 group.
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indicate that endothelial senescence in kallistatin-deficient mouse endothelial cells is
attributed to downregulation of Let-7g and antioxidant genes, and elevation of miR-34a.

Systemic Depletion of Kallistatin Aggravates Aortic Oxidative Stress and Renal
Fibrosis in Diabetic Mice
We generated general kallistatin knockout (KS-/-) mice. Kallistatin null allele (del)
was only detected in KS-/- mice (Figure 4-8 A). Kallistatin depletion was also identified by
the dramatic reduction of protein levels of mouse kallistatin in the kidney of KS-/- mice
(Figure 4-8 B). Kallistatin ablation exacerbated STZ-induced superoxide formation and
NADPH oxidase activity in aortas of diabetic mice, compared with aortas of diabetic WT
mice (Figure 4-8 C&D). Compared with STZ WT mice, kallistatin ablation also caused
the rupture of neointima and thickening of the smooth muscle layer of mouse aorta
(Figure 4-8 C), indicating that kallistatin deficiency exacerbates vascular injury.
Moreover, kallistatin depletion decreased SIRT1 and eNOS expression in aorta, STZ
treatment further downregulated these protein levels (Figure 4-8 E). Regarding diabetesassociated renal injury, we found that kallistatin knockout aggravated renal dysfunction
as increased plasma creatinine and BUN levels (Figure 4-8 F&G). Sirius red staining
result showed that kallistatin depletion markedly increased STZ-induced renal interstitial
fibrosis compared with the kidney of WT diabetic mice (Figure 4-8 H&I). To determine
whether EndMT occurs in diabetes-induced renal fibrosis, we evaluated the expression
of endothelial marker Tie2, and mesenchymal markers such as α-SMA and fibronectin
(Figure 4-8 J). STZ treatment decreased Tie2, but elevated α-SMA and fibronectin
protein levels; and kallistatin deficiency further augmented STZ-mediated effects on
these markers, implicating that more fibrosis emerges in the kidney of diabetic KS-/mice. Collectively, endogenous kallistatin is essential for protection against vascular
injury and renal fibrosis in diabetic mice.
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Figure 4-8 A-E. Kallistatin (KS) depletion exacerbates aortic oxidative stress in STZinduced diabetic mice. (A) Genotyping PCR. (B) Representative western blot of mouse
kallistatin in kidney samples and quantification analysis. (C) Representative images of
aortic superoxide formation labeled by red fluorescence dye DHE. (D) Aortic NADPH
oxidase activity chemiluminescence. (E) Representative western blots of aortic SIRT1
and eNOS. del: kallistatin null gene. n=4. *P < 0.05 vs. WT group; #P < 0.05 vs. WT+STZ
group.
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Figure 4-8 F-J. Kallistatin (KS) depletion exacerbates renal injury and fibrosis in STZinduced diabetic mice. (F) Plasma creatinine levels. (G) Plasma BUN levels. (H)
Representative images of sirius red staining in kidney sections. (I) Quantification of
collagen fraction. (J) Representative western blots of endothelial marker Tie2, and
mesenchymal markers fibronection and α-SMA. n=4. *P < 0.05 vs. WT group; #P < 0.05
vs. WT+STZ group.
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Figure 4-9. Signaling pathway by which kallistatin inhibits endothelial senescence,
oxidative stress and inflammation. Kallistatin through tyrosine kinase stimulates Let-7g
synthesis, inhibits miR-34 and upregulates SIRT1-mediated-eNOS pathway, thereby
elevating catalase, SOD-1/2 and NO levels, leading to blockade of H2O2-modulated ROS
formation, p16INK4a, PAI-1, VCAM-1, ICAM-1, and IL-6 expression, and telomerase
activity in endothelial cells. Genistein, tyrosine kinase inhibitor; NAM, SIRT1 inhibitor; LNAME, NOS inhibitor.
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Discussion
This study demonstrates that endogenous kallistatin plays a protective role in
endothelial senescence, aorta oxidative stress and organ injury, and kallistatin through a
novel mechanism inhibits cellular senescence, oxidative stress and inflammation.
Kallistatin antagonized oxidative stress-induced senescence, as indicated by inhibiting
p16INK4a and PAI-1 levels and increasing telomerase activity in human endothelial cells.
Moreover, kallistatin, via tyrosine kinase, upregulated Let-7g, thus preventing miR-34amediated inhibition of the SIRT1-eNOS pathway. Activation of SIRT1-eNOS signaling
resulted in increased catalase, SOD-1/2 and NO levels, and decreased ROS formation,
VCAM-1, ICAM-1 and IL-6 expression. The signaling mechanism by which kallistatin
inhibits endothelial senescence, oxidative stress and inflammation is shown in Figure 49. To confirm the pivotal role of endogenous kallistatin in protection against endothelial
senescence, we generated endothelial cell-specific kallistatin knockout (KSendo-/-) mice
and general kallistatin knockout mice (KS-/- mice). The protective actions of endogenous
kallistatin in vascular senescence were validated by exacerbated senescence, oxidative
stress and inflammation in mouse lung endothelial cells isolated from KSendo-/- mice.
Importantly, kallistatin is essential for protection of vascular and organ injury as systemic
depletion of kallistatin aggravated vascular oxidative stress and renal interstitial fibrosis
in diabetic mice. The current study indicates an important role of kallistatin in vascular
injury and age-related vascular diseases.

Oxidative stress and inflammation are hallmarks of endothelial senescence
(Erusalimsky, 2009, Salminen et al., 2012). Kallistatin administration has been shown to
attenuate vascular injury and organ damage and aging, in conjunction with reduced
oxidative stress and inflammation in animal models with hypertension, arthritis, diabetes
and sepsis (Shen et al., 2008, Shen et al., 2010, Yin et al., 2010, Li et al., 2014, Lin et
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al., 2015, Yiu et al., 2016). In this study, we showed that kallistatin inhibited H2O2induced oxidative stress and pro-inflammatory gene expression, including VCAM-1,
ICAM-1 and IL-6, in human endothelial cells. Moreover, kallistatin stimulated antioxidant
gene expression, including SIRT1, eNOS, catalase and SOD-2. NO production by eNOS
inhibits superoxide formation and inflammation. Catalase, one of SIRT1’s downstream
antioxidant enzymes, is decreased in H2O2-induced premature senescence. Human
SOD-2 and mouse SOD-1 are antioxidant enzymes and play an important role in the
prevention of endothelial senescence and inflammation (Velarde et al., 2012, Zhang et
al., 2017). Previous reports indicated a reciprocal positive feedback regulation between
SIRT1 and eNOS. SIRT1 has been shown to induce eNOS expression and activity, and
eNOS through NO formation upregulates SIRT1 and maintains vascular homeostasis.
Kallistatin was shown to increase SIRT1 and eNOS synthesis in human endothelial cells
and EPCs (Guo et al., 2015, 2017). Moreover, kallistatin treatment increased eNOS
activity and NO formation in human endothelial cells (Shen et al., 2010). The present
study shows that kallistatin stimulates SIRT1-mediated eNOS pathway, as kallistatininduced eNOS expression was blocked by SIRT1 inhibitor NAM, but kallistatin-mediated
SIRT1 expression was not affected by NOS inhibitor L-NAME. Collectively, kallistatin
through stimulating SIRT1-mediated eNOS pathway protects against senescence,
oxidative stress and inflammation.

Let-7g was recently recognized as an anti-aging miRNA to improve endothelial
functions (Liao et al., 2014). Let-7g negatively regulated apoptosis, senescence and
inflammation in endothelial cells (Zhang et al., 2013; Liao et al., 2014; Liu et al. 2017).
Upregulation of SIRT1 levels was involved in Let-7g-mediated inhibition of endothelial
senescence. In this study, we showed that kallistatin increased Let-7g synthesis, and
kallistatin, via Let-7g induction, stimulated SIRT1 and eNOS, leading to inhibition of
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endothelial senescence, oxidative stress and inflammation in endothelial cells.
Importantly, kallistatin harbors two structural elements, an active site and a heparinbinding domain. Kallistatin’s active site is essential for eNOS and SIRT1 expression
through interacting with a tyrosine kinase in EPCs and endothelial cells (Guo et al. 2015,
2017). It is likely that kallistatin via the active site interacts with tyrosine kinase to
stimulate Let-7g synthesis. Moreover, miR-34a-SIRT1 axis has been regarded to be one
of critical pathways to regulate endothelial senescence (Ito et al. 2010). Our previous
study showed that kallistatin reduced EPC senescence and aorta aging by inhibiting the
synthesis of miR-34a, a pro-senescent miRNA. Consistently, the current study indicates
that kallistatin treatment prevented H2O2-induced miR-34a synthesis in endothelial cells.
Importantly, we found that Let-7g is the upstream regulator of miR-34a in response to
kallistatin treatment. These results indicate that kallistatin protects against endothelial
senescence by upregulating Let-7g to inhibit miR-34a-SIRT1-eNOS pathway.

To further investigate the role of endogenous kallistatin in vascular senescence,
KSendo-/- mice were produced by loxp/Cre technology, and lung endothelial cells from
KSendo-/- mice and WT littermates were isolated and cultured. Kallistatin deficiency in
mouse endothelial cells accelerated replicative senescence and superoxide formation.
Upon

H 2O 2

treatment,

kallistatin

deficiency

further

aggravated

stress-induced

senescence, oxidative stress and inflammation, indicating a protective role of
endogenous kallistatin in maintaining endothelial viability and function. Furthermore,
exacerbated senescence in KSendo-/- endothelial cells was associated with elevation of
miR-34a, and reduction of Let-7g, SIRT1, eNOS, catalase and SOD-1. Thus, Let-7gmediated inhibition of miR-34a-SIRT1-eNOS pathway is suppressed when kallistatin is
deficient. These combined findings support the notion that endogenous kallistatin acts as
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a protective molecule in vascular injury and senescence by stimulating Let-7g, SIRT1
and eNOS, and suppressing miR-34a synthesis.

We generated general kallistatin knockout mice for the first time. There were no
physiological changes except lighter body weight in male KS-/- mice. Kallistatin gene
delivery has been shown to decrease aortic superoxide levels and glomerular
endothelial loss, and reduce renal fibrosis in hypertensive rats (Shen et al., 2008; Shen
et al., 2010). Conversely, kallistatin depletion by neutralizing kallistatin antibody injection
exacerbated renal and cardiovascular oxidative stress, inflammation and organ injury in
hypertensive rats (Liu et al., 2012). Here we used STZ-induced diabetic KS-/- mice to
further confirm the role of kallistatin in vascular oxidative injury and renal fibrosis. In
keeping with previous findings regarding kallistatin’s inhibition in EndMT, organ fibrosis
and vascular injury (Shen et al., 2008; Shen et al., 2010; Guo et al., 2015), kallistatin
depletion aggravated vascular oxidative stress and renal dysfunction and fibrosis. SIRT1
and eNOS expression was significantly suppressed in aorta of KS-/- mice. EndMT
markers were regulated towards pro-EndMT occurrence. Further studies need to
perform to validate whether the interstitial fibrosis is originated from EndMT. These
findings suggest that endogenous kallistatin plays a protective role in diabetes-induced
vascular injury and renal fibrosis.

Overall, this study indicates that kallistatin inhibits cellular senescence, oxidative
stress and inflammation by promoting Let-7g-mediated inhibition of miR-34a-SIRT1eNOS pathway in human endothelial cells. Moreover, endogenous kallistatin plays a
protective role in endothelial senescence, vascular and organ injury. Therefore,
kallistatin could potentially be used as a promising new therapeutic strategy for vascular
aging and dysfunction in humans.
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CHAPTER VI

GENERAL DISCUSSION
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Discussion:
The goal of this research project is to gain insights into the role and mechanism
of kallistatin in vascular injury, senescence and aging, using cultured endothelial cells,
EPCs, STZ-induced diabetic mice, kallistatin deficient mice (KSendo-/- and KS-/-) and C.
elegans. Vascular-related diseases progress with advancing age, which is primarily
attributed to pathophysiological changes in blood vessels (Strait & Lakatta, 2012). The
structural remodeling is featured with neointima thickening, rarefaction of endothelial
cells, increased oxidative stress and inflammation (Asahara et al., 1997, Lakatta, 2002,
Foreman & Tang, 2003). Endothelial cells upon injury insults can undergo EndMT,
senescence or inflammation (Erusalimsky, 2009, Agarwal et al., 2016). We first
demonstrated the efficacy of kallistatin in preventing EndMT, a process mediating
vascular injury, organ fibrosis and tumor progression. Moreover, kallistatin treatment
reduced senescence and aging in cultured EPCs and endothelial cells, mouse aorta,
and C. elegans. We found that the central mechanism for kallistatin in suppression of
EndMT and vascular senescence is mediated by stimulating antioxidant gene
expression. Conversely, endogenous kallistatin deficiency exacerbated endothelial
senescence, oxidative stress and inflammation in mouse endothelial cells. In contrast to
kallistatin’s efficacy in aortic injury and EndMT, systemic kallistatin depletion in KS-/- mice
aggravated diabetes-induced vascular oxidative stress and renal fibrosis. These findings
imply a crucial role of endogenous kallistatin in protection against vascular injury,
senescence and aging.

Our previous studies showed that kallistatin gene delivery inhibited renal fibrosis
in hypertensive rats, cardiac fibrosis in rats with myocardial infarction, and tumor growth
in mice with tumor xenografts (Miao et al., 2002, Gao et al., 2008, Shen et al., 2008).
EndMT is a process mediating neo-intimal thickening by promoting endothelial cell
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differentiation to matrix-producing fibroblasts (Arciniegas et al., 1992). Accumulating
evidence indicates the involvement of EndMT in renal interstitial fibrosis, pulmonary
fibrosis and cardiac fibrosis (Jimenez, 2013, Kong et al., 2014). Aberrant TGF-β-Akt
signaling is primarily activated to drive fibrosis (Meadows et al., 2009). TGF-β promotes
superoxide generation and matrix protein deposition and makes endothelial cells lose
cell-cell junction and be invasive. miR-21, an oncogenic miRNA potentiates TGF-β
responses by inhibiting phosphatase and tensin homolog (PTEN), an inhibitor of Akt
phosphorylation (Kumarswamy et al., 2012). Our current study showed that kallistatin
antagonized TGF-β-induced EndMT by blocking miR-21-Akt pathway and inhibiting
oxidative stress. This study provided new insights that kallistatin via its active site
stimulated eNOS and SIRT1 synthesis and via its heparin-binding domain blocked TGFβ-induced miR-21-Akt pathway. These findings not only revealed the mechanism by
which kallistatin inhibits EndMT but also provided supportive evidence that kallistatin
through inhibiting EndMT protects against vascular injury, organ fibrosis and tumor
progression.

The supply of de novo endothelial cells by EPC pool renders EPCs essential for
vascular repair (Rumpold et al., 2004). However, EPC senescence directly affects its
normal rejuvenation capacity, leading to vascular injury (Heiss et al., 2005). Kallistatin
has been found to increase circulating EPC number in hypertensive rats, and enhance
EPC proliferation, migration, adhesion and tube formation in vitro by activation of PI3KAkt-eNOS pathway (Gao et al., 2014). Consistently, this study showed that kallistatin
inhibited senescence-associated oxidative stress in EPCs by stimulating antioxidant
genes, eNOS and SIRT1 synthesis. SIRT1 is a longevity gene, which is inversely
regulated by miR-34a, a pro-senescent miRNA (Ito et al., 2010). Likewise, miR-21 is
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involved in accelerating cellular senescence in EPCs (Zhu et al., 2013). This is the first
study to demonstrate that kallistatin inhibits EPC senescence associated with reduction
of miR-34a, miR-21 and elevation of eNOS and SIRT1 levels. Inhibition of miR-21 and
stimulation of antioxidant genes may extend kallistatin’s efficacy in EndMT to
senescence. Notably, overexpression of miR-34a abolished kallistatin’s protective effect
on senescence and SIRT1/eNOS stimulation, highlighting the important role of miR-34a
in kallistatin-mediated anti-senescence in EPCs. Type 1 diabetes has been documented
to be associated with aortic senescence (Ota et al., 2010). We used STZ to establish
type 1 diabetes in mice. Our study supports the notion that kallistatin inhibits diabetesinduced aortic senescence and oxidative stress by preventing miR-34a-SIRT1/eNOS
pathway.

Recent study reported that plasma kallistatin levels were positively associated
with leukocyte telomere length in young African Americans (Zhu et al., 2016). Telomere
length is a decisive factor for cellular lifespan, thus kallistatin may have a potential antiaging effect. Indeed, our study showed that kallistatin could suppress in situ superoxide
formation and delay the aging process under heat or oxidative stress conditions in C.
elegans. C. elegans possesses a short lifespan and conservative longevity gene
expression. Two of the pronounced regulatory genes are miR-34 and sir-2.1 (SIRT1
homolog). Kallistatin enhanced C. elegans survival under stress conditions in wild-type
C. elegans but not in miR-34 mutant or sir-2.1 mutant worms, indicating a crucial role of
miR-34 and SIRT1 in kallistatin–regulated longevity. This study demonstrated a role of
kallistatin in delaying the aging process at the organismal level.

It is well known that oxidative stress, inflammation and senescence are intricately
related (Erusalimsky, 2009, Guzik & Touyz, 2017). Oxidative stress and inflammation
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are implicated in various age-associated cardiovascular diseases (Guzik & Touyz,
2017). Our study showed that kallistatin inhibited H2O2-induced endothelial senescence,
associated with elevated antioxidant gene synthesis, and reduced pro-inflammatory
gene expression in human endothelial cells. Using pharmacological inhibitors of eNOS
and SIRT1, this study further revealed that kallistatin through SIRT1 stimulated eNOS
synthesis. Let-7g has been shown to inhibit endothelial senescence, apoptosis and
inflammation (Zhang et al., 2013, Liao et al., 2014). We found that kallistatin through Let7g upregulation prevented miR-34a-SIRT1-eNOS pathway to achieve its anti-senescent,
antioxidant and anti-inflammatory actions. Moreover, kallistatin deficiency in mouse lung
endothelia cells exacerbated senescence, superoxide formation and inflammation in
conjunction with reduced Let-7g and antioxidant gene expression, and elevated miR-34a
synthesis. These studies confirmed that endogenous kallistatin is crucial for reducing
endothelial senescence, oxidative stress and inflammation. These combined findings
provided new insight into the mechanism of kallistatin in protection against endothelial
senescence by regulating Let-7g-mediated miR-34a-SIRT1-eNOS pathway.

In this study, we generated two strains of kallistatin knockout mice, endothelial
cell-specific kallistatin deficient (KSendo-/-) mice and general kallistatin knockout (KS-/-)
mice, using Loxp-Cre recombination technique. To avoid potential embryonic fatality of
KS-/- mice, Cre recombinase activity in KS-/- mice were induced by tamoxifen at four to
five weeks of age. Our previous report showed that kallistatin depletion by neutralized
antibody injection exacerbates renal and cardiovascular injury in hypertensive rats (Liu
Y. et al., 2012). Likewise, we observed that systemic depletion of kallistatin in general
knockout mice worsened aortic oxidative stress and renal fibrosis in STZ-induced
diabetes. Kallistatin deficiency reduced eNOS and SIRT1 levels and elevated oxidative
stress in the aorta of diabetic mice. In parallel with the EndMT study, interstitial fibrosis,
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as indicated by collagen deposition, was further aggravated in kidney of systemic
kallistatin knockout mice with STZ-induced diabetes. Renal fibrosis was associated with
reduced capillary density and increased fibroblasts in diabetic KS-/- mice, as evidenced
by decreased endothelial marker Tie2 and increased mesenchymal marker expression,
fibronectin and α-SMA. These findings confirmed the protective role of endogenous
kallistatin in vascular and organ injury.

Besides kallistatin’s beneficial effects on vascular oxidative stress and organ
fibrosis, our future study will further determine the role of endogenous kallistatin in
vascular senescence and inflammation using general kallistatin knockout mice with STZinduced diabetes. Senescent phenotype and biomarkers in aortas of diabetic KS-/- mice
will be evaluated. Inflammatory gene expression and histologic investigation for
inflammatory cell infiltration in vascular or renal section will be examined. We expect that
the future study could substantiate kallistatin’s crucial role in vascular injury and
senescence by its antioxidant and anti-inflammatory actions.
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Appendix 1
Tissue Homogenization and Plasma Collection
Tissue Homogenization
1. Mince mouse tissues on ice into small pieces and homogenize 10 mg of tissue in 500
µL ice-cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM disodium EDTA, 0.1 mM
EGTA, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate, 0.5% sodium dexoycholate) with
1% protease inhibitor.
2. Homogenize thoroughly and keep tissues on ice for 30 min.
3. Centrifuge the homogenate at high speed (12000 × g) for 30 min at 4°C.
4. Transfer the supernatant into a new tube and store at -80°C.

Plasma Collection
1. Collect whole blood into commercially available anticoagulant EDTA-treated capillary
tubes.
2. Stand the sample on ice at least 30 min.
3. Centrifuge at 3000 rpm for 30 min at 4°C.
4. Collect supernatant (plasma) and store at -80°C.
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Appendix 2
RNA Extraction
1. Add 0.3-0.4 mL of TRIzol Reagent per 1×105-107 cells to lyse the cells. Add 1 mL of
TRIzol reagent per 100 mg of tissue to homogenize samples.
2. Incubate for 20 min at room temperature to permit the complete dissociation of
nucleoprotein complexes.
3. Add 0.2 mL of chloroform per 1 mL of TRIzol Reagent for phase separation.
4. Incubate for 2-3 min at room temperature.
5. Centrifuge the sample for 15 min at 12000 × g at 4°C.
6. Transfer the aqueous phase to a new tube. Add 0.5 ml of isopropanol to the aqueous
phase, per 1 mL of TRIzol Reagent used for lysis.
7. Shake vigorously by hand for 15 s and incubate for 10 min at room temperature.
8. Centrifuge for 10 min at 12000 × g at 4°C.
9. Remove the supernatant, wash the RNA pellet once in 1 mL of 75% ethanol per 1 ml
of TRIzol Reagent used for lysis.
10. Vortex the sample briefly and centrifuge for 5 min at 7500 × g at 4°C.
11. Air-dry RNA pellet for 5-10 min.
12. Dissolve RNA in 20-30 µL DEPC water and incubate in a heat block set at 55-60 °C
for 10-15 min.
13. Determine RNA concentration using Nano-drop instrument.
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Appendix 3
Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
For mRNA RT-PCR:
1. Dilute RNA to 0.2 µg/µL in DEPC H2O.
2. Prepare the 2 × RT master mix on ice (per 20 µL reaction, Life Technologies)
Component

Volume/ Reaction (µL)

10×RT buffer

2.0

25× dNTP Mix (100 mM)

0.8

10× RT Random Primers

2.0

MultiScribe Reverse transcriptase

1.0

RNase Inhibitor

1.0

Nuclease-free H2O

3.2

Total volume:

10.0

3. Mix 2 ✕ RT master mix briefly.
4. Add10 µl of RNA sample to 10 µL of 2 ✕ RT master mix.
5. Mix well and centrifuge, then load the thermal cycler.
6. Run PCR cycles (25°C for 10 min, 37°C for 120 min, 85°C for 5 min and 4°C forever).

For miRNA RT-PCR:
1. Dilute RNA to 0.2 µg/µL in DEPC H2O.
2. Prepare the RT master mix on ice (per 15 µL reaction, Life Technologies)
Component

Volume/ Reaction (µL)

10 × RT buffer

1.50

25 × dNTP Mix (100 mM)

0.15
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MultiScribe Reverse transcriptase

1.00

RNase Inhibitor

0.19

Nuclease-free H2O

4.16

Total volume:

7.00

3. Add 3 µL of 5 × RT primers and 5 µL of RNA sample to each 7 µL master mix.
4. Mix gently and centrifuge, then load the thermal cycler.
5. Run PCR cycles (16°C for 30 min, 42°C for 30 min, 85°C for 5 min and 4°C forever).
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Appendix 4
Quantitative Real-time Polymerase Chain Reaction (qRT-PCR)
For cDNA qPCR amplication
1. Dilute cDNA to 5-10 ng/µL.
2. TaqMan® Gene Expression Assay (20 X, primers and probe) is thawed on ice,
resuspended completely by gently vortexing, then centrifuged briefly.
3. Mix the master mix reagent by gently swirling the bottle.
4. Prepare a PCR reaction mix (per 20 µL reaction):
Component

Volume per 20 µL Sample

Final Concentration

TaqMan master mix (2 X)

10.0

1X

Taqman Primer

1.0

50 nM

Water

7.0

_

18.0

_

Total Volume

5. Mix and transfer 18 µL reaction mix to each well of a 96-well PCR plate.
6. Add 2.0 µL DNA sample to reaction mix per replicate.
7. Seal the plate and centrifuge the plate briefly.
8. Load the plate into the BioRad PCR instrument.
9. Set thermal cycling conditions: UDG incubation at 50°C for 2 min, AmpliTaq Gold
enzyme activation at 95°C for 10 min; PCR cycle (X 40): denature at 95°C for 15 s and
anneal/extend at 60°C for 1 min.

For Small RNA qPCR amplification
1. Obtain a sterile 1.5 mL microcentrifuge tube for each sample.
2. Prepare PCR reaction mix (per 20 µL reaction)
Component

Volume per 20 µL Reaction (µL)
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Taqman Small
RNA Assay (20X)

1.00

Product form RT reaction

1.33

Taqman Master Mix (2X)

10.00

Nuclease-free water
Total volume

7.67
20.00

3. Cap the tube and invert several times to mix.
4. Centrifuge the tube briefly.
5. Transfer 20 µL of the complete PCR reaction mix into each well on a 96-well plate.
6. Seal the plate and centrifuge the plate briefly.
7. Load the plate into PCR instrument.
8. Run the PCR cycle as above.
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Appendix 5
Recombinant Human Kallistatin Purification
1. Culture 293T HEK His-tag kallistatin cells to 90% confluency at 37°C in 5% CO2
incubator.
2. Collect the media and centrifuge at 12000 rpm at 4°C for 30 min.
3. Suspend supernatant in 80% of ammoniums sulfate. Stir for 2-3 hrs at 4°C.
4. Centrifuge at 12000 rpm at 4°C for 30 min.
5. Suspend the pellet in 30 mL of cold ddH2O and then stir at 4°C for 30 min.
6. Dialyze with 1 mM EDTA 4 × of one litter at 4°C using10000 MW dialysis cassette.
Centrifuge at 12000 rpm at 4°C for 30 min.
7. Dialyze with 0.02 M Na2HPO4/0.5 M NaCl, 2 ✕ of one litter.
8. His-Tag resin (4-5 mL). Mix the protein with His-Tag resin, rotate over night at 4°C.
9. Next day stop rotating, let it sit for 1 h. Pack the column and wash with 300 mL of
washing buffer (0.02 M Na2HPO4, 0.5 M NaCl, and 10 mM Imidazole).
10. Elute with 1 mL of 4 ✕ elution buffer and 5 mL of H2O.
11. Dialyze with 1 ✕ PBS and measure protein concentration at OD280.
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Appendix 6
Gelatin Zymography
Prepare the samples:
1. Homogenize samples in ice-cold lysis buffer (pH 5.0, cacodylic acid 10 mM; NaCl 0.15
M; ZnCl 20 mM; NaN3 1.5 mM; Triton X-100 0.01% and proteinase inhibitor). 1:3 (wt/vol).
2. Centrifuge the homogenates for 10 min at 14000 rpm at 4°C.
3. Measure the protein concentration with pierce BCA assay kit (Thermo scientific).

SDS-PAGE
1. Prepare the gel: 4% stacking gel and 10% SDS-PAGE polymerized with gelatin type I
in a final concentration of 1 mg/mL (heat 30 s in microwave).
2. Load samples: loading buffer (non-reducing: 10% SDS; 4% sucrose; 0.25M Tris HCl
and 0.1% bromophenol blue pH 6.8). 50 µg sample is diluted at 3:1 with loading buffer,
without boiling.
3. Run the gel at 15 mA in stacking gel and 20 mA in separating gel at 4°C.

Gel Washing and Staining:
1. Incubate gel in renaturing buffer (2.5% Triton-X-100) for 30 min to remove SDS. First
time 100 mL for 10 min, then change to 100 ml for 20 min.
2. Wash in 150 mL ddH2O for 10-30 min.
3. Incubate gel in developing buffer (50 mM Tris pH 8.0; 5 mM CaCl2; 0.2 M NaCl; 0.02%
Brij-35) for 30 min and change to fresh developing buffer for 16 h at 37°C.
4. Stain gel with Coomassie blue G-250 solution (dissolve 1.25 g Coomassie Blue G-250
in 250 mL methanol, then add 250 mL ddH2O and 50 ml acetic acid) for 30 min.
5. Destain gel with 7% acetic acid, 20% methanol and 73% H2O solution until bands can
be clearly seen.
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Appendix 7
SDS-PAGE and Western Blot Analysis
SDS-PAGE Solutions
Separating gel buffer (pH 8.8): 7.38 g Tris-HCl, 30.7 g Tris-Base, 0.8 g SDS in 200 mL
ddH2O.
Stacking gel buffer (pH 6.8): 7.9 g Tris-HCl, 0.4 g SDS in 100 mL ddH2O.
10% ammonium persulfate (AP): 1.0 g AP in 10 mL ddH2O.
30% acrylamide: 75 g acrylamide, 2 g methylenebisacrylamide in 250 mL ddH2O.
10 ✕ running buffer (pH 8.3): Tris-Base 30.35 g, glycine 144.0 g, SDS 10.0 g. Bring to 1
L with ddH2O.
5 ✕SDS loading buffer (pH 6.8): 1 M Tris-HCl (pH 6.8) 3.75 mL, SDS 1.5 g, DTT 1.16 g,
bromophenol blue 1.5 mg, glycerol 7.5 mL, ddH2O 7.5 mL.

Prepare SDS-PAGE gel:
1. Clean the small and large glass plates with ddH2O and 70% ethanol. Set up the glass
casting apparatus.
2. Prepare polyacrylamide separating gel solution (for 2 gels, 10 wells):
Mixture

10%

ddH2O

4.2 mL

30% acrylamide

3.3mL

Separating buffer

2.5mL

10% AP

55 µL

TEMED

3 µL
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3. Dispense the solution into the casting chamber. Add water slowly until full. Wait 40
min or until polymerized.
4. Prepare polyacrylamide stacking solution (for 2 gels, 10 wells):
ddH2O

1.5 mL

30% acrylamide

375 µL

Stacking buffer

625 µL

10% AP

7.5 µL

TEMED

4 µL

5. Remove the water overlay and dispense the stacking gel solution. Insert the comb.
Allow 30 min for polymerization. Remove the comb.
6.Transfer the polymerized gel to the running apparatus. Pour the 1 ✕ running buffer
until it covers the plates.
7. Load sample (15-50 µg) after boiling at 100°C for 5 min into the wells.
8. Run at 180 V for 40-60 min.

Western Blot Solutions
1 x Transfer buffer (pH 8.3): 3.03 g Tris-Base, 14.4 g glycine, 200 mL methanol, bring to
1 L with ddH2O.
10 X Tris-buffered saline (TBS), pH 7.6: 24.2 g Tris-Base, 80 g NaCl dissolved in 1L
ddH2O. Adjust pH to 7.6 with HCl.
Tris-buffered saline, 0.1% Tween 20 (TBST): Add 1 mL Tween-20 to 1 L 1 X TBS buffer.

Gel transfer
1. Pre-soak sponges, blotting paper and membrane. Add transfer buffer to a plastic tub.
Place the stack to the black side of the plastic holder in the following order: sponge,
blotting paper, membrane, gel, blotting pager and sponge.
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2. Remove all air bubbles and close the plastic holder. Place the transfer sandwich into
the running chamber. Add ice holder and fill with transfer buffer.
3. Run at 100 V at 4°C for 1 h.

Detection using chemiluminescence (ECL+Plus)
1. Rinse the membrane briefly with TBST for 5 min X 2. Block the membrane with 7%
milk in TBST for 1 hr at room temperature on an orbital shaker.
2. Wash twice with TBST, 5 min each.
3. Incubate with primary antibody in 5% milk TBST overnight at 4°C with shaking.
4. Wash the membrane for 3 X 5 min with TBST.
4. Incubate with appropriate secondary antibody (1:5000 to 1: 10000 in 5% milk TBST)
for 1 hr at room temperature. Wash 3 X 10 min with TBST.
5. Apply chemiluminescence chemicals solution A and solution B at a ratio of 1: 1 (500
µL each) at dark, for each membrane add enhancer solution A and B (80 µL each).
6. Drain off excess detection solution and wrap the membrane in Saran Wrap.
7. Capture the chemiluminescent signals using a bio-rad camera-based imager.
8. Use image analysis software to read the band intensity of the target proteins.
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Appendix 8
NAD(P)H Oxidase Activity Assay
Solutions:
Reaction Buffer: 50 mM Na phosphate, pH 7.2, 0.01 mM EDTA, pH 8.0.
5 mM lucigenin (Sigma M-8010, store at RT) in reaction buffer.
2 mM NADH (Sigma N8129, stored at 4°C) in reaction buffer.
2 mM NADPH (Sigma N1630, store at -20°C) in reaction buffer.
Activity Procedure:
1. Let the TD-20/20 luminometer warm up for 5 min and set up as follows:
a. Inj 1: OFF, Inj 2: OFF
b. Set up: Delay = 5 sec, Integrate = 900 sec, Replicate = 1
c. Set up: 888, set sensitivity to 60.1 %
2. Once set up is complete, prepare NADPH blanks in cuvettes and record light intensity.
reaction buffer

1.37 mL

5 mM lucigenin

75 µL (250 µM)

2 mM NADH or NADPH

55 µL (100 µM)
1.5 mL

3. Prepare sample reaction mixtures in cuvettes and record light intensity.
reaction buffer

1.35 mL

5 mM lucigenin

75 µL (250 µM)

2 mM NADH or NADPH

55 µL (100 µM)

sample

20 µL
1.5 mL

4. Calculate activity as follows:
(sample intensity - blank intensity)

= rlu/mg protein/min

protein conc. (mg/mL) x 0.02 mL x time (min)
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Appendix 9
Transfection of MicroRNA-34a Mimic or Let-7g Inhibitor
1. One day before transfection, culture cells (in 12-well plate) in 500 µL of growth
medium without antibiotics such that they will be 30-50% confluent at the time of
transfection.
2. For each well to be transfected, prepare RNAi duplex-Lipofectamine® RNAiMAX
complexes as follows:
A. Dilute 6 pmol miRN-34a mimic or control siRNA in 50 µL Opti-MEM® I Reduced
Serum Medium without serum. Mix gently.
B. Mix Lipofectamine™ RNAiMAX gently before use, then dilute 1 µL in 50 µL OptiMEM® I Reduced Serum Medium. Mix gently.
C. Combine the diluted RNAi duplex with the diluted Lipofectamine™ RNAiMAX. Mix
gently and incubate for 10-20 min at room temperature.
3. Add the RNAi duplex-Lipofectamine® RNAiMAX complexes to each well containing
cells. This gives a final volume of 600 µL and a final RNA concentration of 10 nM. Mix
gently by rocking the plate back and forth.
4. Incubate the cells 6-12 h at 37°C in a CO2 incubator until you are ready to assay for
gene knockdown. Medium may be changed after 4-6 h.
5. Perform qRT-PCR to detect transfection efficiency.
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Appendix 10
Telomerase Activity
Extract Preparation
1. Pellet the cells or tissue, wash once with PBS, repellet, and carefully remove all PBS.
2. Resuspend the cell pellet in 200 µL of CHAPS lysis buffer/105-106 cells.
3. Incubate the suspension on ice for 30 min.
4. Spin the sample in a microcentrifuge at 12,000 x g for 20 min at 4°C.
5. Transfer 160 µL of the supernatant into a fresh tube and determine the protein
concentration. For cell extract concentration should be 10-750 ng/µL.
6. Aliquot and quick-freeze the remaining extract on dry ice, and store at -80°C.
Required Controls and Samples:
5X TRAPEZE® RT Reaction Mix*

5.0 µL

Taq Polymerase (5 units/µL)

0.4 µL (2 Units)

Nuclease Free Water

17.6 µL

Samples:

2.0 µL

(TSR8 dilutions, positive extract control, telomerase negative, NTC, experimental
samples +/- heat treatment)
TOTAL VOLUME 25.0 µL
PCR Amplification
1. Set-up the real-time experiment to include the following PCR parameters.
30°C 30 min 1 cycle
95°C 2.0 min 1 cycle
94°C 15
59 °C 60 sec

✕ 45

*45°C 10 sec
* Temperature and stage where the Real-time fluorescent data should be collected.
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Appendix 11
Genotyping and DNA Electrophoresis
DNA Extraction from Tail Biopsy
1) Cut 0.5 cm tail from each mouse at 3 week-old age.
2) Transfer tail biopsy to 150 µL lysis solution 1 (500 mL: 1.25 mL 10 M NaOH; 2 mL 0.5
M EDTA; 496.75 mL ddH2O). Incubate samples in 90°C heater block for 45 min.
3) Centrifuge briefly and add 150 µL Solution 2 (pH 7.4, 40 mM Tris). Vortex briefly.

Genotyping:
1. Primers: Serpina3c-A1Loxp-F, Serpina3c-A1Loxp-R; Seripina3c-Frt-F, Seripina3c-FrtR; Cre-F, Cre-R; LRL-040-A1 Loxp-F, LRL-040-A1 Loxp-R.
2. Prepare a PCR reaction mix in a PCR tube (per 25 µL reaction):
Component

Volume per 25 µL Sample (µL)

AmpliTaq Gold
360 master mix

12.5

Forward Primer

1.0

Reverse Primer

1.0

DNA

2.0

Water

8.5

Total Volume

25.0

3. PCR cycling parameters as below:
95 °C 2 min
95 °C 30 sec
63 °C 30 sec

X 35

72 °C 25 sec

122

72 °C 10 min
4°C Finished

DNA Electrophoresis
1. Prepare 3% agarose gel (3 g in 100 mL 1 X Tris-acetate-EDTA buffer, heated in
microwave for 1-2 min).
2. Cool down the agarose solution to around 60 °C, add a final concentration of 5 µg/mL
ethidium bromide and mix well.
3. Place comb into casting tray and pour the solution to casting tray.
4. Let casting tray sit for 5 min at 4°C or 30 min at room temperature.
5. Add 2 µL 10 X DNA loading buffer to each sample.
6. Set up gel electrophoresis unit. Fill gel box with 1 X TAE until complete covered.
7. Load molecular weight marker and samples into gel wells.
8. Run gel at 130 V for 40 min.
9. Visualize DNA products with UV light.
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Appendix 12
Isolation of Mouse Lung Endothelial Cells
Digestion Lung Samples
1. Remove whole lungs of the mouse. Wash whole lungs with serum-free basal-DMEM.
Chop the lung tissue using sterile, disposable blades to very small pieces.
2. Transfer the pieces into a 15-mL centrifuge tube containing 1 X working dilution of
collagenase digestive solution (7–10 mL per 0.5 g of wet tissue).
3. Digest the lung at 37°C for 45 min under continuous horizontal shaking (300 r.p.m.).
Quench the lung-digestive solution mixture with an equal volume of complete-DMEM.
4. Strain the lung digest through the 70-mm cell strainers by releasing the lung digest on
the cell strainer using a 5-mL pipette.
5. Restrain cell suspension through a 40-µm cell strainer into a 50-mL centrifuge tube.
6. Centrifuge the 50-mL tube at 300 X g at 4°C for 10 min.
7. Decant the supernatant and resuspend the cell pellet in 10 mL of complete-DMEM.
8. Centrifuge the 50-mL tube at 300 X g at 4°C for 10 min.
9. Decant the supernatant and resuspend the cell pellet in 5 mL of MACS buffer (0.5 %
BSA, 2 mM EDTA in PBS). Determine cell number.

Magnetic Labeling
10. Add 90 µL of buffer per 107 total cells to the cell pellet. Add 10 µL of CD31
microbeads per 10⁴ total cells. Mix well and incubate for 15 min in the refrigerator.
11. Wash cells by adding 1−2 mL of buffer per 10⁴ cells and centrifuge at 300 X g for 10
min. Aspirate supernatant completely.
12. Resuspend up to 10⁵ cells in 500 µL of buffer.

Magnetic Separation
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13. Prepare column by rinsing with 3 mL MACS buffer for each LS column.
14. Apply cell suspension onto the column. Collect flow-through containing unlabeled
cells.
15. Wash column with 3 ✕ 3 mL MACS buffer. Collect unlabeled cells that pass through
and combine with the flow-through from step 3.
16. Remove column from the separator and place it on a suitable collection tube.
17. Pipette 5 mL MACS buffer onto the column. Immediately flush out the magnetically
labeled cells by firmly pushing the plunger into the column.
18. Centrifuge for 5 min. Resuspend cells with EBM-2 media and culture cells in gelatincoated dishes.
19. After 10 days’ culture, digest cells and repeat steps 10-19 for second round of CD31
immunoselection.
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Appendix 13
Immunocytochemistry
1. Aspirate the culture media of cells grown in 6- or 12-well plates, then cover cells with
4% formaldehyde diluted in 1 × PBS.
2. Allow cells to fix for 15 min at room temperature.
3. Aspirate fixative, rinse 3 times in 1 × PBS for 5 min each.
4. Block specimen in blocking buffer (1 × PBS / 3% BSA / 0.2% Triton X-100) for 60 min.
5. Aspirate blocking buffer, apply diluted primary antibody in antibody dilution buffer (1
×PBS / 1% BSA / 0.3% Triton X-100) and incubate overnight at 4°C.
6. Rinse 3 times in 1 × PBS for 5 min each.
7. Incubate specimen in fluorochrome-conjugated secondary antibody diluted in antibody
dilution buffer for 1-2 h at room temperature in the dark.
8. Rinse 3 times in 1 × PBS for 5 min each.
9. Counterstain the nuclei with Hoechst 33343 (5 µg/mL in PBS) for 5 min.
10. Rinse 3 times in 1 × PBS for 5 min each and mount.
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Appendix 14
Picosirius Red Staining
Solutions:
0.2% Phosphomolybdic Acid (PMA): 0.2 g PMA in 100 mL ddH2O.
1% aqueous solution Sirius red: 0.5 g in 50 mL ddH2O.
Sirius red in picric acid: 10 mL of 1% aqueous solution, 90 mL saturated picric acid, pH
2.0. Let the solution sit for 24 h at room temperature.

Procedure
1. Deparaffinize and rehydrate paraffin-embedded sections to water.
2. Incubate slides in 0.2% PMA for 5 min.
3. Rinse briefly in distilled water.
4. Stain in picosirius red solution (pH 2.0) for 90 min.
5. Rinse in 0.01 N HCl, change solution in jars for 3 or 4 times.
6. Dehydrate and mount.
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Appendix 15
SA-β-gal Staining
Solutions
Staining solution: 40 mM citric acid/sodium phosphate (pH 6.0), 0.15 M NaCl, 2 mM
MgCl2.
100 ✕ Staining solution supplement A: 500 mM potassium ferrocyanide.
100 ✕ Staining solution supplement B: 500 mM potassium ferricyanide.
Fixative solution: 2% formaldehyde, 0.2% glutaraldehyde in 1 ✕ PBS
β-gal staining solution: For each 35 mm well to be stained, add 930 µL staining solution,
10 µL staining supplement A, 10 µL staining supplement B, 50 µL 20 mg/mL X-gal in
DMF into a polypropylene container. Adjust pH to 5.9-6.1.

Procedure
1. Rinse the cell culture plate one time with 1 ✕ PBS (2 mL for a 35 mm well).
2. Add 1 mL of fixative solution to each 35 mm well. Allow cells to fix for 10-15 min at
room temperature.
3. Rinse the plate two times with 1 ✕ PBS.
4. Add 1 mL of the β-gal staining solution to each 35 mm well. Incubate the plate at 37°C
overnight in a dry incubator (no CO2).
5. Check the cells under a microscope (200 ✕ magnification) for the development of blue
color.
6. For long-term shortage of the plates, remove the β-gal staining solution and overlay
the cells with 70% glycerol. Store at 4°C.
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